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Abstract 
Depression is a widespread psychiatric disorder that represents a major cause of 
disability worldwide. Besides the significant mortality rate due to suicide, depression 
has been associated with an increased prevalence of coronary artery disease and type-2 
diabetes. In spite of the accumulated knowledge on the heterogeneous collection of 
symptoms that characterize the disease, much has yet to be discovered about its patho-
physiology. Risk factors include stressful life events, endocrine abnormalities, and genet-
ic predispositions interacting with the environment. The development of animal models 
of depression have made it possible to study the behavioral and neurobiological corre-
lates of the disease, although only a subset of the symptoms that characterize the human 
syndrome can be reproduced and studied in the animal. Clomipramine, a well-known 
tricyclic antidepressant, acts in an apparently paradoxical fashion when repeatedly ad-
ministered to neonate rats. The treatment induces in the adult a series of behavioral and 
neurobiological effects similar to a depressive syndrome. The mechanisms underlying 
the phenomenon are still unknown, although hypotheses have been formulated on the 
potential depressogenic effects of clomipramine-dependent inhibition of REM sleep and 
alterations of the monoaminergic circuitry in a developing brain. 
In the present dissertation, I report the results of an in-depth investigation of the 
behavioral and neurobiological correlates of the neonatal clomipramine administration 
model of depression, not yet described or only partially analyzed in the literature. For 
each of the experiments, groups of Sprague-Dawley rats were subjected from the 5th to 
the 21st post-natal day to a protocol of clomipramine administration (20 mg/kg i.p., 
twice a day). The animals were compared with groups of rats treated with saline injec-
tions according to an identical schedule. Both groups of animals were tested for 
locomotor activity and despair behavior with the forced swim test, for anhedonic behav-
ior with the sucrose preference test and for exploratory activity and anxiety trait with 
the elevated plus maze test. In all behavioral tests performed, clomipramine-treated an-
imals showed abnormalities, although sometimes subtle, that can be attributed to de-
pression-like symptoms, compared to saline-treated animals. Morphometric studies 
conducted by means of magnetic resonance imaging, performed to detect possible vol-
umetric abnormalities in brain regions usually associated with depression, showed a 
significant decrease in brain volume in treated animals, together with a significant en-
largement of the lateral ventricles, but no significant changes in the hippocampus. Inves-
tigations of the neurobiological correlates of the clomipramine treatment yielded results 
that include: 1) Brain-derived neurotrophic factor levels were significantly decreased in 
the hippocampus, but not in the cortex, of treated animals; 2) serotonin transporter ex-
pression, measured as optical density of the immunohistochemical labeling of the mark-
er in brain sections, was decreased in the hippocampus and cingulate cortex of treated 
animals compared to the controls; 3) expression of the glial fibrillary acidic protein, a 
marker of astrocytes, was by neonatal treatment affected in relation with age and sex. 
On the other hand, hippocampal neurogenesis rate and hippocampal granule neuronal 
morphology were not significantly affected by treatment. The data suggest sex-
dependent differences in the effects of clomipramine, with female rats being more re-
sponsive than males to the neonatal treatment. Furthermore, the behavioral symptoms 
as well as the neurobiological consequences of the treatment appeared to reduce with 
aging, to the point of almost complete recovery at an advanced age  
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The neonatal clomipramine administration model was further characterized by 
testing the reaction of animals to an acute stressful event, in this case restraint stress re-
alized by immobilizing animals with a wire mesh, on the rationale that such events can 
trigger or precipitate depression in humans and that a similar phenomenon may be ob-
served in the animal model. For this study, a group of untreated rats, i.e. animals that 
were left undisturbed in their cages throughout their development, were added to the 
experimental design. An interaction between early life treatment and stress in adult-
hood was found in several experiments. Importantly, untreated animals showed sub-
stantial differences compared to the other two groups, suggesting that a significant frac-
tion of the observed effects rather than being directly attributable to the pharmacologi-
cal properties of clomipramine, may in fact depend on the procedure as a whole, includ-
ing handling, injection discomfort, and separation from the mother. Overall, the studies 
reported here provide important elements for the evaluation of the efficacy and congru-
ency of the early clomipramine treatment model of depression. 
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1 Introduction 
1.1 Human depression 
Depression is a widespread psychiatric disorder characterized by a combination 
of symptoms that interfere with a person’s ability to work, sleep, study, eat, and enjoy 
once-pleasurable activities. In its more severe forms, depression is a debilitating and po-
tentially devastating disease, whose neurobiological bases are still poorly understood.  
1.1.1 Epidemiology and symptoms of human depression 
Depression affects over 120 million people worldwide, and is projected to be-
come the second most prevalent cause of illness-induced disability by 2020 according to 
the World Health Organization (Murray and Lopez, 1997). In addition to the higher mor-
tality associated with suicide, depression complicates the prognosis of a wide variety of 
other chronic conditions, and depressed patients are more likely to develop coronary ar-
tery disease and type 2 diabetes. Despite its prevalence and high impact, understanding 
the etiology and pathophysiology of depression has been an elusive enterprise for the 
scores of dedicated researchers, both in basic science and in clinical research. 
The reasons for the apparent paradox are, first and foremost, the intrinsic diffi-
culty in observing subtle pathological alterations in the brain that justify the syndrome, 
and the fact that most depression cases occur idiopathically, in the absence of easily 
identifiable causal and/or precipitating factors. 
The most common time of onset of the first episode of depression is between the 
ages of 30 and 40, while a second peak is between 50 and 60.  
Depression can be diagnosed on the basis of a large variety of symptoms which, 
according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 
2000), include: 
• emotional symptoms: depressed mood, with feeling of sadness or emptiness, re-
duced interest and pleasure-seeking in activities usually enjoyed, suicidal 
thoughts or intentions; 
• neurovegetative symptoms: sleep impairments (not enough or too much sleep), 
loss of appetite and weight; 
• physical symptoms: loss of energy or a significant reduction in energy level; 
• cognitive symptoms: difficulties in concentrating, holding a conversation, paying 
attention, or making decisions that used to be made easily. 
 
The complex picture of symptoms, the course and severity of the illness, and its 
response to antidepressant treatment are all highly variable, suggesting that the term 
depression may in fact encompass distinct etiological and pathophysiological entities. To 
date, aside from the clinical assessment, no reliable diagnostic tests for depression are 
available, which makes it difficult to differentiate mild depression from “normal” reac-
tions to hardships (Berton and Nestler, 2006). 
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1.1.2 Endogenous vs. reactive depression 
An “old-fashioned” classification of depression distinguishes reactive depression 
from endogenous depression. According to this hypothesis, reactive depression is a di-
rect consequence of a specific, highly stressful event or sequence of events, whereas en-
dogenous depression, presenting no apparent external causative agent, is the result of a 
biochemical or genetic abnormality. This classification has been largely abandoned, also 
because it has proven of little use in predicting disease course, suicidal risk, or response 
to therapy (Pies, 2009). 
Understanding the nature and causes of depression has long been the focus of in-
tense research, but many aspects of the disease are still a matter of heated discussion. It 
is not always clear which neurobiological correlates are causes and which are effects of 
depression, although some theories have been developed to propose a background for 
the onset of depression, including psychological, psycho-social, hereditary, evolutionary, 
and biological arguments. Herein only the biological factors will be treated, with the in-
tent that it will be possible to make a comparison between human and animal depres-
sive syndrome. 
1.1.3 Monoamine hypothesis and antidepressant therapy 
The monoamine hypothesis of depression proposes that a depletion in the levels 
of serotonin, norepinephrine, and dopamine in the central nervous system (Fig.1.1) con-
 
Fig. 1.1 Monoamine hypothesis of depression: a) neurotransmission in a healthy condition: monoamines 
are released in the synaptic cleft and bind to the postsynaptic receptors. In part, monoamines are recy-
cled through the re-uptake mechanism; b) neurotransmission in depression: lower levels of neuro-
transmitters are responsible for depressive disorders; c) neurotransmission restored by antidepressant 
treatment: the inhibition of re-uptake increases the levels of monoamines at the synaptic cleft, allowing 
a normal neurotransmission (Castren, 2005). 
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stitute the basis of the pathophysiology of depression (Delgado, 2000).  This hypothesis 
originated from early clinical observations: 1)  reserpine, a drug used in the control of 
high blood pressure that depletes central monoamine stores, was found to induce in a 
subset of patients depressive effects, among which motor retardation and sedation 
(Delgado, 2000; Krishnan and Nestler, 2008); 2) imipramine and iproniazid, two struc-
turally unrelated compounds that were not developed as antidepressants, but as an an-
tihistamine and an antitubercolotic respectively, showed antidepressive effects by ele-
vating mood of patients (Castren, 2005).  
For many years, the neurobiological bases of depression have been linked to the 
mechanisms of action of antidepressants. By elevating the levels of neurotransmitters, 
alleviation of the symptoms of depression is obtained, although  the experimental deple-
tion of monoamines in healthy individuals does not alter mood (Krishnan and Nestler, 
2008). This observation suggests that the cause of depression is far from being a simple 
deficiency of central monoamines, but rather the result of the contribution of many fac-
tors. 
For many years, the pharmaceutical industry focused the development of antide-
pressant agents, as shown in Table 1.1, on the rationale of the monoamine hypothesis, 
i.e. that, increasing the levels of the monoamines serotonin, dopamine, and noradrena-
line at the synaptic cleft, either by inhibiting the neuronal reuptake mechanism, such as 
the selective serotonin reuptake inhibitors (SSRI) do, or by inhibiting degradation, like 
monoamine oxidase inhibitors, can help to restore the normal neurotransmission thus 
inducing an amelioration of the symptoms of depression. Both classes of drugs act by 
immediately increasing the levels of monoamines, but their beneficial effects on pa-
tients’ mood are manifested only after a few weeks of treatment (Krishnan and Nestler, 
2008). 
Recent drug discovery strategies aim at the development of novel antidepressant 
agents whose target is other than the recovery of neurotransmission. One important 
purpose of these new classes of drugs is to obviate the delay of the onset of therapeutic 
effects observed with classical amine-based therapies. Actions of the novel drugs (see 
Table 1.2) are directed to disparate targets that range from some classes of receptors (κ 
opioid, CB1 cannabinoid, melatonin, NPY, etc.) to regulatory pathways of inflammation 
and blood coagulation, to gene transcription. All the novel antidepressant therapies are 
still at a pre-clinical stage of research (Berton and Nestler, 2006). 
 
Class of antidepressant agents Mode of action Examples 
Tricyclics Inhibition of mixed noradrenaline 
and serotonin reuptake  
Imipramine, desipramine 
Selective serotonin reuptake inhib-
itors (SSRIs) 
Inhibition of serotonin-selective 
reuptake 
Fluoxetine, citalopram 
Noradrenaline reuptake inhibitors 
(NRIs) 
Inhibition of noradrenaline-
selective reuptake 
Atomoxetine, reboxotine 
Serotonin and noradrenaline 
reuptake inhibitors (SNRIs) 
Inhibition of mixed noradrenaline 
and serotonin reuptake 
Venlafaxine, duloxetine 
Monoamine oxidase inhibitors  Inhibition of monoamine oxidase A 
(MAOA). Inhibition of MAOB does 
not have antidepressant effects 
Tranylcipromine, phenelzine 
Lithium Although its many effects, it is still 
unknown the antidepressant 
mechanism of lithium 
 
Atypical antidepressants Unknown Bupropion, mirtazapine, tiamepti-
ne 
Table 1.1 - Currently available antidepressant treatments (Berton and Nestler, 2006). 
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Antidepressant agents Target Actions 
κ opioid receptor an-
tagonists 
Opioid peptide 
dynorphin 
Systemic or site specific (nucleus accumbens) administration 
blocks dynorphin action, responsible for depression-like behaviors 
in rodents. κ antagonists have been found to reduce the immobili-
ty in the rodent model of forced swim test (Mague et al., 2003). 
CB1 cannabinoid re-
ceptor agonists or an-
tagonists 
CB1 receptor 
and its endoge-
nous ligands  
CB1 receptors are highly expressed in brain regions such as amyg-
dala and the disruption of their activity elicits anxiety-like behav-
iors in rodents. This effect suggests that anxiolytic tone is inher-
ently mediated by endogenous cannabinoids (Kathuria et al., 
2003). 
Proinflammatory pa-
thways regulators 
Cytokines Proinflammatory molecules (like cytokines and interferon-γ) are 
responsible for sickness behavior, a sort of depressive syndrome 
characterized by a decrease in a number of activities, like feeding, 
exploration, and sexual activity in animals; humans medicated 
with interferon-α showed depressive symptoms that were suc-
cessfully treated with antidepressants (Dunn et al., 2005).  
Melatonin receptor 
agonists 
(ex. Agomelatine) 
Melatonin re-
ceptor 
Melatonin has anti-depressive like effects in animal models, may-
be interfering with hypothalamic-pituitary-adrenal axis; in a trans-
genic mouse model of depression, with decreased glucocorticoid 
receptor in the brain, agomelatine treatment reduced the immo-
bility time in the forced swim test (Barden et al., 2005). 
Galanin ligands Serotonergic 
and noradre-
nergic neurons 
Galanin inhibits the firing and release of noradrenergic and sero-
tonergic systems besides anatomically coexisting with these two 
major monoamines in several brain regions. Galanin is implicated 
in cognition, nociception, feeding and sexual behavior and it is 
supposed to play an important role in stress (Holmes et al., 
2005b). 
Neuropeptide Y (NPY) 
agonists 
NPY receptor  Anxiolitic effects of NPY are suggested by, for example, the evi-
dence that there is an up-regulation of NPY mRNA levels in the 
amygdala after chronic stress, and that transgenic rats with over-
expression of NPY are behaviorally less sensitive to stress 
(Charney, 2004). 
Histone Deacetylase 
(HDACs) inhibitors  
Gene transcrip-
tion 
There are observations on drugs inhibiting gene transcription with 
anti-depressant effects (ex. imipramine). Brain regions involved in 
these actions are not known with certainty yet (Berton and 
Nestler, 2006). 
Agents interfering with 
tissue plasminogen 
activator (tPA) action 
tPA tPA is known to promote stress-induced synaptic plasticity and 
anxiety-like behavior. Corticotropin-releasing factor can up-
regulate tPA activity in the amygdala consequently influencing 
neuronal activation and behavioral response (Matys et al., 2004). 
Table 1.2 - Novel antidepressant therapies in preclinical phase of drug discovery research. 
Non-pharmacological forms of antidepressant therapy range from psychothera-
py, recommended for mild depression, to electroconvulsive therapy, a shock treatment 
that, inducing changes in brain chemistry,  has been demonstrated to be highly effective 
in reversing symptoms of depressive syndromes resistant to pharmacological treatment 
(Berton and Nestler, 2006). Another non-pharmacological therapy is represented by 
deep brain stimulation, which, stimulating a region of the cingulate cortex , has been 
shown to improve depressive symptoms (Berton and Nestler, 2006).  
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1.1.4 Dysregulation of the Hypothalamic-Pituitary-Adrenal Axis and stress 
The so-called hypothalamic-pituitary-adrenal (HPA) axis is an anatomical com-
plex constituted by the hypothalamus, the hypophysis, and the adrenals glands that 
through both neuronal and hormonal interactions and feedback loops controls and regu-
lates physiological processes such as digestion, temperature, immune response, sexuali-
ty, energy usage, and mood. The HPA axis plays a crucial role in how the organism reacts 
to stressful events, injury, and trauma. 
The regulation of HPA axis is illustrated in Fig. 1.2. The corticotropin-releasing 
factor (CRF) is released by parvocellular neurons of the paraventricular nucleus of the 
hypothalamus under an excitatory influence from the amygdala. Through the 
hypophyseal portal system, CRF reaches the anterior pituitary and stimulates it to re-
lease the adrenocorticotropin hormone (ACTH). ACTH, via systemic blood circulation, 
reaches the adrenal cortex inducing the release of glucocorticoids.  By means of negative 
feedback, glucocorticoids inhibit CRF and ACTH synthesis and release, and, consequent-
ly, their own synthesis (Nestler et al., 2002; Barden, 2004). 
 
Fig. 1.2. Regulation of HPA axis, decribed in the text. Adapted from Nestler et al., 2002. 
Small but significant increases in serum concentrations of glucocorticoids, in par-
ticular cortisol, in depressive patients suggest a role of a dysfunctional HPA axis in the 
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pathophysiology of depression (Krishnan and Nestler, 2008). Indeed, some depressed 
patients present excessive activation of the HPA axis, an abnormality that can be re-
versed to correct functionality by antidepressant treatment (Nestler et al., 2002; Barden, 
2004). In this respect, a possible mechanism by which antidepressants, such as the tri-
cyclic agents amytriptiline (Reul et al., 1993) and imipramine (Kitayama et al., 1988) and 
the monoamino oxidase A inhibitor moclobenide (Reul et al., 1994), could act is the in-
crease, through stimulation at the genomic level, in the concentrations of cellular corti-
costeroid receptors to make the HPA system more susceptible to feedback inhibition by 
cortisol (Barden, 2004). 
HPA axis is strongly activated by stress (Aguilera, 1994; Aguilera and Rabadan-
Diehl, 2000), which is widely acknowledged to be a precipitating factor of depressive 
syndromes especially in genetically predisposed individuals. Although stress per se has 
not been demonstrated to cause depression, the early phases of depression  are associ-
ated with enhanced responsivity to stress. Early life experiences are considered a rele-
vant modulator of the development of individual vulnerability to stressful events and, 
consequently, to depression (Kubera et al., 2011). 
Stress decreases BDNF expression (Duman and Monteggia, 2006), increases pro-
inflammatory cytokines concentrations (O'Connor et al., 2003), decreases neurogenesis 
and induces dendritic atrophy through BDNF- and/or HPA-axis-dependent mechanisms 
(Duman and Monteggia, 2006), affects hippocampal function and structure (Lucassen et 
al., 2010). All these actions contribute to the concept that stress should be regarded as a 
major risk factor for depression. The importance attributed to stress in establishing de-
pression is reflected in the large use of stress-induced animal models of depression, 
where animals that are subjected to a single or to repeated stressful events at any age 
show behavioral and neurochemical markers of depression (Kubera et al., 2011). 
 
1.1.5 Genes and environment 
Across the life span, stressful life events can influence the onset and course of de-
pression, as said in section 1.1.4, but not all people succumb to depressogenic effect of 
stress (Caspi et al., 2003). The diathesis-stress model of depression attempts to explain 
individual’s behavior as a result of genetic vulnerability together with individual’s sensi-
tivity to stressful events (Caspi et al., 2003).Behavioral genetic research, supporting this 
prediction, aims at the documentation of a relationship between genes and depression. 
 The disorder is highly inheritable, even if no genetic abnormalities have been 
linked with certainty yet (Nestler et al., 2002). It should be noted that the identification 
of genetic alterations that may be responsible for the disorder has proven difficult not 
just in the case of depression, but more in general for psychiatric disorders, due to the 
complexity of each one. It is likely that the respective genetic bases lay in alterations of 
groups of genes, rather than of a single gene (Nestler et al., 2002).  
One of the most discussed studies in this research field is the one performed by 
Caspi and collaborators that was aimed at: a) demonstrating of a correlation between 
the functional polymorphism in the promoter region of the serotonin transporter gene 
(SLC6A4) and vulnerability to develop a depressive syndrome and b) investigating of the 
impact of gene variation on life stress influence on depression (Caspi et al., 2003). The 
longitudinal study was not able to demonstrate a direct association between the seroto-
nin transporter gene and depression, even if the interaction gene*environment extends 
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to the natural development of depression in a representative sample of subjects fol-
lowed (Caspi et al., 2003).  
1.1.6 The inflammatory hypothesis of depression 
Immunological mechanisms have been included among the neurobiological cor-
relates that characterize depression. During inflammation, cells of the immune system 
produce pro-inflammatory cytokines such as interleukine-1α and β (IL-1α and IL-1β), 
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) which elicits various endo-
crine, autonomic, and behavioral alterations that together coordinate the “nonspecific 
symptoms of sickness” (Dantzer et al., 2008; Lucassen et al., 2010). According to recent 
hypotheses, pro-inflammatory cytokines may not only induce sickness behavior, but also 
a depressive syndrome in physically ill patients who have never suffered previous de-
pressive episodes or mental disorders (Dantzer et al., 2008).  
These patients appear feverish, nauseated, lacking appetite, and not interested in 
any social activity; they get tired easily and have a fragmented sleep; moreover, they 
show a depressed and irritable mood, and a certain degree of cognitive impairment, 
such as lack of attention and memory (Dantzer et al., 2008). These symptoms largely 
overlap the set of typical symptoms of depression. 
In rodents, central or systemic administration of IL-1β or TNF-α induces sickness 
symptoms, like decreased motor activity, sociality, liquid and food intake, and altered 
sleep pattern, cognition, and pain-sensitivity (Dantzer et al., 2008).  
In humans, depressive symptoms develop in a third of patients treated with the 
recombinant human cytokines interleukine-2 (IL-2) and interferon- α (IFN-α), as anti-
cancer therapies (Dantzer et al., 2008). Furthermore, increased levels of chemokines and 
adhesion molecules, of cytokines and acute-phase proteins have been observed in de-
pressed patients (Raison et al., 2006).  
Peripherally secreted cytokines access the brain through three different routes: 
1) leaky regions of theblood brain barrier, 2) binding to specific transporters expressed 
in the brain endothelium, and 3) activation of vagal afferent fibers that transmit the sig-
nal to specific brain nuclei which than serves as a relay station to other brain nuclei in-
cluding the paraventricular nuclei in the hypothalamus. Once in the brain, a central cy-
tokine network, made of neurons and glia, expresses cytokine receptors and amplify the 
signal, inducing behavioral and hormonal effects. These changes are reflected in the al-
teration of the metabolism of serotonin, noradrenaline, and dopamine in brain areas be-
longing to the limbic system, and in the stimulation of the HPA axis in the secretion of 
hormones (Raison et al., 2006). 
The driving factor for inflammation in depressed patients could be psychological 
stress: stress is a common risk factor for depression and it is known that in laboratory 
animals a large variety of stressors, such as inescapable tailshock, footshock, social isola-
tion, immobilization, restraint, and open-field exposure, increase expression of pro-
inflammatory cytokines, with IL-1ß being the most explored cytokine in regard, in brain 
regions involved in the emotionality and in the periphery (O'Connor et al., 2003). 
Paroxetine has been found to improve IFN-α-induced depression (Musselman et 
al., 2001) and it has been proven that antidepressants inhibit the production and/or re-
lease of pro-inflammatory cytokines and induce the production of anti-inflammatory cy-
tokines. These observations suggest that antidepressants, reducing inflammatory pro-
cess, induce an amelioration of the symptoms of depression, even if not all symptoms 
seem to be responsive, such as fatigue or psychomotor slowing (Raison et al., 2006). 
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Some studies, however, have failed to find a correlation between inflammation 
and depressive severity or have found disparate and occasionally opposite correlations 
for different pro-inflammatory cytokines (Raison et al., 2006). These observations sug-
gest that it is not possible to assert with certainty that inflammation has a role in the 
pathophysiology of depression (Raison et al., 2006). 
1.2 Neurobiological correlates of depression 
1.2.1 Adult hippocampal neurogenesis and neuroplasticity 
Neurogenesis is the process of generating new cells in the brain from neural pro-
genitor stem cells. Early neurodevelopmental studies, including Ramon y Cajal’s classical 
observations, asserted that the formation and differentiation of neurons in the mamma-
lian brain is restricted to the prenatal and early postnatal age (Ming and Song, 2005). 
The notion of a hard-wired brain in the adulthood was so engrained that the later dis-
covery of adult neurogenesis came as a surprise (Ming and Song, 2005). It is currently 
well established that the phenomenon occurs in at least two brain areas, the 
subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate gyrus of the 
hippocampus, whereas outside these two regions neurogenesis seems to be limited or 
non-existing (Ming and Song, 2005; Ehninger and Kempermann, 2008). The fact that 
adult neurogenesis occurs in all mammalians species studied to date, including humans 
(Eriksson et al., 1998),  suggests an important role for the phenomenon (Fuchs and 
Gould, 2000), although to this day its full significance is not well understood.  
In principle, of course, the generation of new functional neurons in the adult 
brain should be regarded as the ultimate expression of structural plasticity.  On the oth-
er hand, given the numerical and topographical limitations of neurogenesis, the relation-
ship between the phenomenon and the general domain of neuronal plasticity is complex 
and hard to pinpoint. In rodents, it seems that the formation and survival of new neu-
rons is correlated with learning and short-term memory (Gould et al., 1999a; Gould et 
al., 1999b; Kempermann, 2002; Leuner et al., 2004). Hippocampal cell proliferation in 
rodents has been reported to be positively influenced by many factors, such as voluntary 
exercise (Farmer et al., 2004), sleep deprivation (Grassi Zucconi et al., 2006), and envi-
ronmental enrichment (Kempermann et al., 1997).  Furthermore, neurogenesis in the 
rodent hippocampus has been shown to increase following antidepressant treatment 
(Malberg et al., 2000; Dranovsky and Hen, 2006; Warner-Schmidt and Duman, 2006; 
Paizanis et al., 2007; Krishnan and Nestler, 2008). These observations may represent a 
link between hippocampal neurogenesis and depression. Antidepressants’ regulation of 
neurogenesis seems to range from cell proliferation to differentiation and survival 
(Malberg et al., 2000). Interestingly, all tests performed with different classes of antide-
pressant drugs resulted in an increased proliferation and survival of new neurons in the 
dentate gyrus of rodent hippocampus (Paizanis et al., 2007; Pittenger and Duman, 
2008). On the other hand, actively blocking neurogenesis does not elicit a depression-
like effect, as shown in the open-field, the light-dark choice, and the elevated plus maze 
tests, although the block affects hippocampus-dependent forms of fear-conditioning, 
long-term spatial and working memory (Sahay and Hen, 2007). 
These results may support the idea that the increase in hippocampal neurogene-
sis is a sort of driving force to enhance the antidepressant response but, at the same 
time, there are no observations that confirm that impairments in the rates of neurogene-
sis are involved in the core features of depression (Krishnan and Nestler, 2010). Even in 
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Fig. 1.3 Rodent hippocampal circuitry: dia-
gram of the neural network. CA3 receives 
projections from layer II neurons of 
entorhinal cortex (EC) through the direct 
connection of the perforant pathway (PP) 
and through an indirect connection, in 
which the dentate gyrus is a middle pas-
sage. CA3 pyramidal neurons convey the 
information to CA1 pyramidal neurons 
through Schaffer collaterals and CA1 py-
ramidal neurons send back-projections to 
deep-layer neurons of the EC. CA1 receives 
direct projections from EC through the 
temporoammonic pathway too. Granule 
cells of the dentate gyrus also project from 
interneurons of the hilus which send back 
inhibitory or excitatory stimuli (adapted 
the presence of convincing data correlating depression-like symptoms in the rodent 
with a dysfunctional hippocampal neurogenesis, much has yet to be explored in the hu-
man hippocampus and the limited number of publications on this issue offer contrasting 
evidence. Indeed, postmortem analyses of hippocampal tissue from depressed patients 
have not revealed a decreased neurogenesis, but rather an increase in neuronal and glial 
density in conjunction with decreased neuronal cell body size (Stockmeier et al., 2004). 
On the other hand, it has been shown that antidepressant treatment induces an increase 
in neural progenitor cells both in non-human primates (Perera et al., 2007) and in hu-
mans (Boldrini et al., 2009). 
Elevated levels of glucocorticoids, produced by HPA axis when acitivated by 
stressful events, represent a negative factor for hippocampal neurogenesis rate and neu-
roplasticity. Glucorticoids have been shown to reduce the birth of new neurons in the 
hippocampal granule cell layer (Fuchs and Gould, 2000) and to induce atrophy of CA3 
pyramidal neurons, with a reduction of apical dendritic branch points and of the length 
of apical dendrites, and a loss of dendritic spines specialized in the reception of excitato-
ry glutamatergic synaptic inputs (Sapolsky, 2000). Transient glucorticoid overexposure 
induces an alteration of neuronal morphologic features, thus it can be deleterious to ex-
plicit hippocampal memory pathways (Sapolsky, 2000). Impaired hippocampal function 
consequent to such damages may contribute to some of the observed cognitive abnor-
malities of depression. Re-growth of dendritic processes could occur if glucocorticoid 
exposure stop (Sapolsky, 2000).  
Ont the other hand, antidepressant therapy has been shown to positively influ-
ence hippocampal cell proliferation and plasticity.  Fluoxetine, a well-known SSRI anti-
depressant agent,  modulates synapse density in CA1 and CA3 after 5 days of treatment, 
but CA3 with a higher peak only after 14 days of treatment; this asynchrony in the 
synaptoplasticity effects may be due to the delayed integration of new granule cells into 
the hippocampal circuitry. It is known that neurogenesis is enhanced within two weeks 
of fluoxetine treatment and that newborn hippocampal cells directly innervate and acti-
vate only CA3 pyramidal neurons through mossy fibers (Fig. 1.3), so this could be the 
reason of the later onset of new synapses in CA3 (Hajszan et al., 2005). It is presumable 
that hippocampal synaptic remodelling is, if not the first, an early stage of restoration of 
normal functioning of hippocampus (Hajszan et al., 2005). 
In a study in the olfactory-bulbectomy model of depression in rodents, chronic 
administration of amytriptiline, a tricyclic antidepressant, was found to block the de-
16 Cristina Tognoli 
crease in spine density in dentate gyrus, CA1 and CA3 cell layers (Pittenger and Duman, 
2008). More studies are needed to test the action of different classes of antidepressant 
drugs since it has been observed that reduction in dendritic arborization is 
blocked/reversed by chronic administration of tianepine, an atypical antidepressant, but 
not by fluoxetine, in a chronic stress model of depression (Pittenger and Duman, 2008). 
1.2.2 Brain-Derived Nerve Factor 
Neurotrophic factors, besides the regulating action on neuronal growth and dif-
ferentiation, are associated with plasticity and survival of adult nerons and glia. 
At the end of the 1990s, the hypothesis of a role of neurotrophic factors in the 
pathophysiology of depression raised the interest of many scientists. According to the 
hypothesis, an altered expression of neurotrophin levels may contribute to the devel-
opment of depression by inducing neuronal atrophy and cell loss in key limbic brain re-
gions involved in depression, such as the hippocampus (Nestler et al., 2002; Duman and 
Monteggia, 2006). 
Attention has been focused for many years on the brain-derived nerve factor 
(BDNF), possibly the most prevalent neurotrophic factor in adult brain. The great major-
ity of blood BDNF is localized in platelets, from which it is released following platelet ac-
tivation. In depressed patients, blood levels of BDNF are not different from those in 
healthy controls, but it is possible that in depressive syndromes the ability of platelets to 
release BDNF is altered (Castren and Rantamaki, 2010). It is unclear whether serum 
BDNF levels reflects brain BDNF levels, since BDNF does not cross the blood-brain bar-
rier (BBB); plasma BDNF could influence brain regions in which BBB is leaky, such as 
parts of the hypothalamus (Castren and Rantamaki, 2010). A large amount of literature 
has shown that stress can cause damage and atrophy of neurons in several brain struc-
tures and a decrease in BDNF expression, maybe via a stress-induced glucocorticoid 
mechanism (Smith et al., 1995), but chronic antidepressant treatment has been shown 
to restore BDNF levels in these regions (Nibuya et al., 1995). Nowadays, BDNF signalling 
is believed to play an important role in the mechanism of action of antidepressants in 
the improvement of depressive symptoms, although the role of BDNF itself in the onset 
of depression is still unclear (Castren and Rantamaki, 2010). 
Signs of hypomania following intratechal BDNF administration were observed in 
patients with amyotrophic lateral sclerosis, thus supporting the hypothesis of a role for 
BDNF in regulating mood (Castren and Rantamaki, 2010). In animal models of depres-
sion, in contrast to the observed anti-depressant-like effects when injected into hippo-
campus (Shirayama et al., 2002) and midbrain (Siuciak et al., 1997), BDNF increased 
pro-depressant effects when administered into the ventral tegmental area and nucleus 
accumbens (Eisch et al., 2003). In a rat model of chronic mild stress, BDNF protein ex-
pression was found decreased in the hippocampal dentate gyrus, but not in the CA re-
gion (Gronli et al., 2006). In a study on a chronic unpredictable stress model of depres-
sion, however, the opposite effect was found (Larsen et al., 2010).  
It is worth mentioning a study performed in transgenic mice with a single-
nucleotide polymorphism in the gene encoding BDNF, whose exposure to a stressful en-
vironment induced an increase in anxiety-like behaviors that were not normalized by 
fluoxetine treatment (Chen et al., 2006). These results demonstrate that BDNF may rep-
resent an example of the gene-environment interaction responsible of the onset of mood 
disorders, possibly of a depressive syndrome, as previously discussed in section 1.1.5,  
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1.2.3 Neuroanatomy of depression 
The limbic system, constituted by a group of brain structures surrounding the 
brainstem (the cingulate gyrus, hippocampus, the hypothalamus, amygdala, antherior 
thalamic nuclei, the prefrontal and the enthorinal cortex) was identified as playing a role 
in the experience of emotion and in the storing of memory (Palazidou, 2012). The emer-
gence of neuroimaging techniques , like magnetic resonance imaging (MRI), provided ev-
idence  of the malfunction of the brain structures and the connections that form the lim-
bic region in depressed patients, suggesting a central role of this system in the patho-
physiology of depression (Palazidou, 2012). The prefrontal cortex (PFC), the amygdala 
and the hippocampus are the brain structures most studied in relation to depression 
(Palazidou, 2012). 
The hippocampus is the most widely studied region in relation to depression be-
cause it is fundamental for learning and memory functions, it is rich in corticosteroid re-
ceptors providing regulatory feedback to the HPA axis, and it is one of the two regions in 
which neurogenesis occurs in adulthood (see section 1.2.1). 
In the human depressed patients, MRI studiesof the hippocampus, provide infor-
mation about the correlation among neuronal atrophy, volumetric changes and depres-
sion in vivo while in postmortem studies it is possible to investigate the cellular aspects 
responsible of volume changes.  A high number of post-mortem studies showed morpho-
logical and morphometric changes of the hippocampus of depressed patients, including 
volume loss (Bremner et al., 2000; Sheline, 2000; MacQueen et al., 2003; Neumeister et 
al., 2005), gray matter alterations and neuropil reductions (Bremner et al., 2000; 
Sheline, 2000). Therefore, it is not clear why the hippocampus is decreased in volume 
since neuron density is not reduced (Stockmeier et al., 2004). A few studies, reporting no 
differences between patients and healthy subjects (Ashtari et al., 1999; Vakili et al., 
2000) maybe did not consider effects of sex, age, anatomical definition, type of depres-
sive syndrome, or antidepressant treatment response (Schmidt and Duman, 2007; 
Kempton et al., 2011). 
Other reductions in the volume of brain regions have been found in the frontal 
cortex, caudate nucleus, putamen, pituitary gland and core nuclei of the amygdala 
(Sheline, 2000). Besides the results above described, a very recent meta-analysis study 
reported in depressed patients compared to controls about a significant increase in vol-
ume of adrenal gland, basal ganglia, and thalamus and a significant enlargement of lat-
eral ventricles (Kempton et al., 2011). 
1.3 Animal models of depression 
Models of depression have been developed to reproduce the symptoms of de-
pression in laboratory animals in order to study behavioral patterns and biological 
mechanisms. It is difficult to realize an animal model that perfectly represents human 
depression: animals lack consciousness of self, self-reflection and consideration of oth-
ers as well as traits of depressed mood, low self-esteem, and suicidality. On the other 
hand, other hallmarks of depression can be reproduced and investigated in animals, in-
cluding behavioral, physiological, hormonal, morphological, and neurochemical modifi-
cations (Berton and Nestler, 2006; Nestler and Hyman, 2010). 
In rodents there is a set of symptoms of depression, common to human depres-
sion, that can be reproduced and investigated. They include: 
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• changes in appetite and/or weight gain, that can be easily measured in animals; 
• alterations in sleep pattern: disturbances in circadian rhythm, especially insom-
nia or excessive sleeping, can be measured using electroencephalography; 
• anhedonia: a marked loss of interest in pleasurable and rewarding actions can be 
measured with intracranial self-stimulation, preference for a palatable reward 
(for example, sucrose) and social withdrawal; 
• anxiety-like behavior: this symptom has a high prevalence in depression; in ani-
mals it can be investigated with behavioral paradigms, such as the elevated plus 
maze test and the open field test, or with neurochemical analyses, like hormonal 
dosage of cortisol; 
• behavioral despair: the inhability to cope with a helplessness and inescapable 
situation is a common feature measured in animals with the forced swim test and 
the tail suspension test; 
• fatigue or loss of energy: reduced activity in home cage or other stimulating envi-
ronments with tests that measure locomotor activity; 
• difficulty in performing even easy tasks: this can be reflected in the scarce hy-
giene of animals, like dirty and ruffled coat; 
As said above, some symptoms, like recurrent thoughts of death/suicide and feel-
ings of guilt cannot be modeled in animals but other investigations can be performed on 
neuroanatomical features, like hippocampal neuronal arborization and death, or neuro-
chemical analysis of depression-targeted substances, like neurotrophic factors (Cryan 
and Holmes, 2005). 
1.3.1 Validation of an animal model of depression 
The minimal requirements for animal models of depression are face, construct 
and pharmacological validity. 
Face validity is the degree of homology of the model with human depression. The 
symptomatology in rodents ranges from social isolation, lack of appetite with weight 
loss, anhaedonic behavior, circadian alterations, and HPA axis abnormalities. It is possi-
ble that these symptoms are not present at the same time and persist only for a certain 
period of animal’s life (Willner and Mitchell, 2002; Krishnan and Nestler, 2010). 
Construct validity consists in the causality of the syndrome: the etiology should be 
the more possible resembling the one that triggers human depression. This is a challeng-
ing requirement: today we still do not know the definitive causes of depression, even if 
we have learned a lot about factors characterizing it (Willner and Mitchell, 2002; 
Krishnan and Nestler, 2008, 2010). 
Pharmacological validity, known also as predictive validity, is met when depres-
sive-like behaviors of the animal model are reversed by the same treatment modality 
that is effective in humans. Anyway, this is not a mandatory requirement, since some an-
imal models are reproduced in order to study the antidepressants’ mechanism itself, 
that is still largely unknown (Krishnan and Nestler, 2010). 
Another potential requirement that could be taken in account is pathological va-
lidity: animals should show the same physiological, cellular, and molecular changes ob-
served in post-mortem studies on brains of depressed patients (Krishnan and Nestler, 
2010). 
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Besides these demanding conditions, of course it is desirable that the behavioral 
changes can be monitored objectively and that the animal model is reproducible be-
tween investigators. 
1.3.2 Animal models of depression 
As mentioned above, many of the symptoms of depression cannot be easily inves-
tigated in laboratory animals and the lack of known genes involved in vulnerability to 
depression are major impediments in depression research (Nestler et al., 2002). 
In Table 1.3, the most widely used animal models of depression are presented. A 
substantial fraction of all available animal models of depression rely on exposure to var-
ious types of stressors and response to antidepressant therapy, but some of these, such 
as the forced swim test (Kitayama et al.) and the tail suspension test, are no more con-
sidered as real models of depression, but have been found to be useful paradigms in the 
pharmaceutical industry to assess the efficacy of new medications in the screening stage 
of drug development (Nestler and Hyman, 2010). The learned helplessness model can be 
included in this type of tests because they all have a common paradigm: to subject ani-
mals to an acute, short-duration (only a few minutes) stress to make them to respond in 
an active or passive way and maybe provoking a despair behavior measurable as time 
spent in immobility during the stressful event. An acute antidepressant treatment in an-
imals that underwent these short stressful events is really effective; but criticisms 
against the validity of these animal models were raised, since it is known that in human 
depression antidepressants are administered chronically for weeks or months to obtain 
an effect within a few weeks, but single doses are able to improve symptoms in animals 
in a few hours or days (Nestler and Hyman, 2010). Even if the learned helplessness 
model simulates only an increased risk for precipitation of depression (Willner and 
Mitchell, 2002), it is still one of the most studied models of depression, especially for the 
demonstrated involvement of a genetic predisposition to develop signs of helplessness 
symptoms (Cryan and Mombereau, 2004). 
Chronic stressors used on normal adult animals induce symptoms of anhedonia, 
that can be measured as a reduced consumption of a sucrose solution, which chronic, 
but not acute, treatment with antidepressants is able to reverse. Chronic stressors used 
to induce depression in laboratory animals include chronic mild or unpredictable stress 
and psychosocial stress. Chronic mild or unpredictable stress is represented by a set of 
different stressful events to which the animals are subjected: cage tilting, inversion of 
light/dark cycle, immersion in cold water, food or liquid deprivation, and paired housing 
are some of the most common stressors used (Nestler et al., 2002). 
Chronic social defeat is a paradigm of psychosocial stress, in which rodents are 
subjected to repeated bouts of social subordination. The intensity of this kind of stress is 
more severe than that seen in most humans and it induces not only anhedonia, but social 
withdrawal too (Nestler and Hyman, 2010). Prolonged exposure of adult rodents to so-
cial isolation induces anhedonia as well, and chronic antidepressant treatment is effec-
tive in reversing this symptom(Nestler and Hyman, 2010). It has been shown that early 
adverse life events can trigger an abnormal development: traumas in childhood may re-
sult in increased sensitivity to stress exposure in adulthood and increased vulnerability 
to stress-induced disorders, depression included (Heim and Nemeroff, 2001). 
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Early-life handling and maternal separation, have been proven to be valid models 
MODEL METHOD OF INDUCTION 
BEHAVIORAL CORRELATES OF 
DEPRESSION 
STRESS IN ADULT-
HOOD 
  
Learned helplessness Animals are exposed to uncontrollable and inescapable 
shocks and consequently fail to escape from a situation in 
which escape is possible (Vollmayr and Henn, 2001). 
Short lasting deficits in escape, 
cognitive and rewarded behav-
iors, such as sucrose preference 
Chronic 
mild/unpredictable 
stress 
Animals are exposed to a series of mild stressors (isolation 
or crowded housing, food or water deprivation, inversion of 
light/dark cycle, cage tilting, wet bedding, low room tem-
perature, noises, etc.) presented in a continuous unpredict-
able fashion every day for at least two weeks (Nestler and 
Hyman, 2010). 
Long lasting changes of behav-
ioral parameters: decreased su-
crose preference and intracranial 
self-stimulation, poor fur condi-
tion 
Psychosocial stress An example is the resident-intruder paradigm, in which an 
adult male (intruder) is introduced into the home cage of an 
unfamiliar aggressive conspecific (resident) (Rygula et al., 
2005); similarly, in another paradigm, an aggressive male 
can be introduced into a stable social group. A further para-
digm is the creation of social groups and then mixing them 
(Blanchard et al., 2001). 
Anhedonia, decreased locomotor 
activity and social withdrawal 
 
  
DEVELOPMENTAL    
Early-life or prenatal 
stress  
Maternal separation for 1-24h per day during the first two 
postnatal weeks (Sterley et al., 2011). Prenatal stress is per-
formed by exposing dams, in the early stages of pregnancy, 
to repeated footshock or in the late stages to mild stress of 
handling (Ward et al., 2000). 
Increased anxiety- and depres-
sion-related behaviors and ab-
normal locomotor activity 
Clomipramine and 
other antidepressant 
agents 
Chronic drug administration in the postnatal period for two 
or three weeks induces a depressive syndrome in adulthood 
(Willner and Mitchell, 2002). 
Decreased sexual activity, ag-
gressive behavior and rewarded 
behaviors; increased immobility 
in the FST  
LESIONS   
Olfactory 
bulbectomy 
Bilateral removal of the olfactory bulbs induces changes in 
synaptic strength and loss of spine density in limbic circuitry 
(Song and Leonard, 2005) 
Hyperactivity in open field, im-
paired spatial learning in water 
maze  
PHARMACOLOGICAL   
Reserpine  Reserpine induces a depletion of central stores of neuro-
transmitters (Delgado, 2000) 
Motor retardation and sedation 
Psychostimulant 
withdrawal 
Escalating doses of cocaine or amphetamine administration 
for several days (Barr et al., 2002) 
Increased immobility in the FST 
and tail suspension test; reward 
deficits 
IMMUNE STIMULA-
TION 
  
Proinflammatory cy-
tokines 
Central or systemic administration of IL-1β or TNF-α induces 
sickness behavior, a syndrome similar to depression 
(Dantzer et al., 2008). 
Decreased motor activity, sociali-
ty, liquid and food intake, and 
altered sleep pattern, cognition, 
and pain-sensitivity 
GENETIC   
Selective breeding Specific criteria concerning performance in a behavioral 
test, such as TST, are used for selection and consequent 
breeding of animals (El Yacoubi et al., 2003). 
Great variability within the mod-
els 
Genetically engi-
neered mice 
Genes for serotonine and norepinephrine receptors and 
transporters, dopamine ß-hydroxylase, monoamino oxidase 
A, BDNF and CREB constitute the candidate genes for the 
genetic mutant mice (Cryan et al., 2002; Urani et al., 2005). 
Behavioral syndromes are 
dipendent from the gene select-
ed 
Table 1.3. Summary of common rodent models of depression 
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of depression: the stressful event to which pups are subjected has life-long behavioral 
and neuroendocrine rebounds, that can be reversed by antidepressant treatment 
(Nestler and Hyman, 2010). Moreover, mouse models of postnatal stress have been pro-
duced to study the interaction between a specific gene and the environment (Holmes et 
al., 2005a). 
Chronic administration of antidepressant drugs like clomipramine, zimeldine, 
and citalopram in the early postnatal period have been shown to induce in the adult rats 
a spectrum of symptoms resembling those of depression: decreased aggressive behavior 
and sexual activity in males, anhedonia, REM sleep abnormalities, and motor agitation in 
some tests and motor retardation in other tests. These long-lasting symptoms were 
shown to be reversed by antidepressant treatment or REM sleep deprivation (RSD) 
(Vogel et al., 1990a). 
A lesion model is a non-stress based animal model that relies on the assumption 
that deficits in regulation of neuronal circuitry can cause depression. The olfactory 
bulbectomy in rodents induces a disruption of the limbic-hypothalamic axis, thus the 
behavioral abnormalities observed are not only consequence of loss of smell, but largely 
of compensatory mechanisms of neuronal reorganization, included changes in synaptic 
strength and loss of spine density in limbic regions, like hippocampus and amygdala 
(Song and Leonard, 2005). The hyperactivity observed in the open field paradigm is re-
versed by antidepressant treatment (Cryan et al., 1999). 
Reserpine treatment induces decreased locomotor activity and reduced body 
temperature by non-selectively depleting monoaminergic stores in the central nervous 
system. Iproniazid, a drug developed against tubercolosis and now used as antidepres-
sant, can reverse the effects of reserpine on hypomotility in rats. It is still not clear how 
reserpine lowers mood and which monoamine is predominantly made unavailable by its 
action. The validity of the reserpine model is still under investigation (O'Neil and Moore, 
2003). 
Psychostimulant withdrawal induces in humans typical symptoms of a depres-
sive syndrome; in rodents, amphetamine or cocaine withdrawal may help to compre-
hend the neurobiological mechanisms that underlie the development of depression 
(Barr et al., 2002). The symptoms are transient but are highly analogous to some aspects 
of human depression. 
Another model of depressive-like behavior is represented by the administration 
of TNF-α in rodents. Animals show a spectrum of symptoms such as anorexia, decreased 
social behavior and locomotor activity, as well as activation of the hypothalamic-
pituitary-adrenal axis. All these symptoms characterize the sickness behavior, that re-
semble a depressive syndrome (Kaster et al., 2012). It has been proved that antidepres-
sants inhibit the production and/or release of pro-inflammatory cytokines and induce 
the production of anti-inflammatory cytokines. These observations suggest that antide-
pressants, reducing inflammatory process, induce an amelioration of the symptoms of 
depression, even if not all symptoms seem to be responsive, such as fatigue or psycho-
motor retardation (Raison et al., 2006). 
Genetic approaches offer the possibility to identify the genes that are determi-
nant to develop a depressive syndrome and to reproduce in animals the human condi-
tions. Several approaches were exploited to find target genes involved in the onset of 
depression and the result is that depression is a syndrome characterized by multiple ge-
netic mutations (Bucan and Abel, 2002). Genetically engineered mice have been success-
fully developed to investigate depression; nowadays, mouse mutants target 
monoaminergic receptors and transporters and enzymes necessary for monoaminergic 
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synthesis and degradation (Urani et al., 2005). The limitations of this kind of models is 
that the effects of only one gene at a time can be studied, thus animals produced do not 
represent entirely a realistic model of depression. 
Also selective breeding of mice and rats is a successful strategy, taking advantage 
of differences in the individual responsiveness in paradigm of depression- or antide-
pressant-like behavior such as immobility levels in the FST, or susceptibility to learned 
helplessness (El Yacoubi et al., 2003). 
1.3.3 Sex differences in animal models of depression 
Epidemiologic research has repeatedly reported about the difference between 
men and women in the rates and courses of depression; in particular it has been found 
that in females morbidity is twice as common as in males, and females had the first epi-
sode at a younger age compared to males (Marcus et al., 2005). 
The serotonergic system was found to be implied in a sexual dimorphism: in de-
pressed women, cerebrospinal fluid levels of 5-hydroxy-indoleacetic acid was found to 
be increased, and, in general, whole brain serotonin synthesis and 5-HT2 receptor bind-
ing attitude were significantly decreased compared to men (Dalla et al., 2010). For what 
concerns animals, normal female rats showed increased serotonergic activity, synthesis 
and levels of metabolites in a study of sex differences in rat brain serotonin (Carlsson 
and Carlsson, 1988). 
There is also recent evidence about sex differences in antidepressant response: 
women appear to respond in a different way according to the class of antidepressant 
agents, maybe due to a hormonal “background”. Indeed it has been shown that meno-
pause influences the response to therapy (Dalla et al., 2010). 
The investigation of sex differences in the neurobiology of depression and anti-
depressant response is important to improve diagnosis of depression and may provide 
gender-based antidepressant therapies which take account of sex differences in phar-
macokinetics and pharmacodynamics (Dalla et al., 2010). 
Most animal models of depression were produced using male rodents and only 
later they were applied in females, but with certain difficulties due to not only basal sex 
differences but also to differences that emerged after certain manipulations. The explo-
ration of these differences could be useful to understand the heterogeneous develop-
ment of depression in men and women and the sex influence in response to antidepres-
sant treatment. 
It is largely acknowledged that female rats do not express learned helplessness 
behavior as males do and even a complex study did not succeed in demonstrating that 
sexual hormones may be imputable for the lack or decreased expression of the learned 
helplessness behavior in females (Dalla et al., 2008). 
In response to a set of chronic mild stressful events, female and male rats showed 
different performances in behavioral assessments: 1) both males and females showed a 
decrease in sucrose preference, but males at a major degree; anyway, sucrose intake has 
been shown to be higher in unstressed females compared to males, so these basal evi-
dence could suggest that this paradigm is not an appropriate parameter; 2) females 
spent less time in explorative activity in an open field compared to males; 3) in response 
to an additional novel stressor, the FST, females showed a higher despair behavior 
(Dalla et al., 2005). Anyway, in FST per se, not only as an additional stressor in a stress-
induced model of depression, females showed a higher immobility compared to males 
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(Dalla et al., 2011). Furthermore, only females showed increased corticosteroid levels 
and serotonergic activity (Dalla et al., 2005). 
In the model of lipopolysaccharide–induced sickness many differences between 
males and females were found: a higher rewarded behavior with the sucrose preference 
in females, a reduced food intake only in males, a decreased locomotor activity mainly in 
males, an HPA axis activation only in females, dimorphic hypothalamic serotonergic re-
sponse, an hippocampal activation of serotonergic activity only in females, and an in-
creased serotonergic activity in prefrontal cortex and striatum only in females 
(Pitychoutis et al., 2009). 
Collectively, sex differences are influenced in both the behavioral and neurobio-
logical aspects. In human society it must be taken in account also that psychosocial fac-
tors may mediate or influence the individual predisposition to the risk of depression on-
set and the response to antidepressant treatments. 
Despite the fact that none of the presently available animal models is able to 
shape all aspects of depression, there are useful paradigms that help in the investigation 
and improvement of antidepressant drugs and in the validation of neurobiological theo-
ries about depression. 
 
We chose to investigate correlates of depression in the neonatal clomipramine 
model because: 1) it can be produced without specialized equipment; 2) it does not re-
quire traumatizing animals; 3) the effect of treatment lasts for months, allowing to con-
duct a large variety of tests; 4) it is a valid model to study altered brain functions and 
physiology; 5) there is a large amount of literature demonstrating its validity as model of 
depression, as described in the following section. 
1.4 The neonatal clomipramine model in the rat 
Clomipramine is the 3-chlorinated derivative of imipramine (Fig. 1.4) and both 
drugs belong to the family of the tricyclic antidepressants. 
 
Fig. 1.4 - Chemical structure of clomipramine hydrochloride. 
Clomipramine (Anafranil®) principally acts as a reuptake inhibitor of serotonin, 
dopamine, and noradrenaline in the synaptic space and it is also a powerful REM-sleep 
suppressant. Because of its mixed action that implies numerous side effects, it does not 
represent the preferred agent prescribed for an antidepressant therapy. Anyway, it is 
frequently used for the treatment of obsessive compulsive disorder (OCD), panic disor-
der, chronic pain and narcolepsy too. 
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A large amount of data from literature support the hypothesis, made for the first 
time by Vogel and co-workers, of a paradoxical depressant action of clomipramine in ro-
dents neonatally treated (Vogel et al., 1990a). In spite of the thorough investigation of 
this animal model, it is still not clear if the endogenous depression, affecting adult ani-
mals that were exposed to clomipramine in early life (CLI animals), is caused by the 
suppression of REM sleep or by the interference on aminergic neurotransmission of an 
immature central nervous system (CNS). 
Vogel’s work was inspired by Mirmiran and colleagues, who evaluated the impact 
of neonatal REM sleep on adult behavioral development. REM sleep deprivation (RSD), 
accomplished by clomipramine administration during the neonatal period, caused in 
male rats, as adults, sexual and locomotor impairments, and, in advanced age, a perma-
nent increase of REM sleep and a higher number of REM sleep onset periods (Mirmiran 
et al., 1981; Vogel et al., 1990a). Mirmiran and co-workers interpreted the results ob-
tained as a relevant indication about the importance in the early life of a normal REM 
sleep pattern for the development of normal adult behavior and sleep. Vogel, on the oth-
er side, interpreted Mirmiran’s findings as evidence of a complex syndrome that resem-
bles human endogenous depression. It is known that depressed patients show an altera-
tion of sexual and locomotor activity, and an impaired REM sleep pattern, thus suggest-
ing that if adult rats, neonatally exposed to clomipramine, show the same symptoms, 
they could be considered valid models of human endogenous depression (Vogel et al., 
1990a). 
Each animal model of depression needs to be tested for its validity, and in par-
ticular, according to Vogel’s proposal to validate the neonatal clomipramine model, ani-
mals should show: 1) several behavioral abnormalities typical of human endogenous 
depression such as decreased aggressiveness, sexual activity, and pleasure-seeking ac-
tivity, as well as motor agitation or retardation; 2) an alteration of the normal REM sleep 
pattern, since depressed patients usually exhibit decreased REM latency, increased REM 
sleep onset periods, increased REM phasic events, and, after a period of RSD, an abnor-
mal REM sleep rebound; 3) an amelioration of the behavioral abnormalities induced by 
treatment with antidepressant agents like in human endogenous depression (Vogel et 
al., 1990a). 
Vogel and collaborators carried out a study to validate the animal model. Behav-
ioral abnormalities observed in CLI rats, compared to animals treated with a saline solu-
tion (Sal animals) as a control group, were presented as follows: 
1) in a test for aggressive behavior, pairs of rats, each pair consisting of one CLI 
animal and one SAL animal, fought in response to randomly delivered intermittent foot 
shock: CLI rats consistently lost in shock-induced aggression, showing significantly few-
er offensive fighting responses, and significantly more defensive fighting responses 
(Vogel et al., 1988); 
2) in a set of nonsexual pleasure-seeking assessments, CLI rats showed, when 7 
months old, diminished response to hypothalamic intracranial self-stimulation at both 
single and multiple stimulus intensities, a lower interest in the exploration of a novel ob-
ject in an open field, but no differences compared to Sal rats in the sucrose and saccha-
rine consumption, even if the tests were monthly repeated from age 3 months to age 10-
11 months (Vogel et al., 1990a); 
3) in sexual testing of males, three strains of 3-month old rats were compared: 
even if Sprague-Dawley and Wistar rats exhibited a basal lower sexual activity than 
Long-Evans rats, CLI rats from each strain showed a lower sexual activity in terms of 
number of mounts, intromissions, and ejaculations and of mount latency and post-
The clomipramine model of depression in the rat  25 
ejaculatory pauses, but only in Long-Evans rats the decrease was significant (Vogel et al., 
1990a); 
4) in two different locomotor activity tests, CLI animals showed contrasting be-
havior: hyperactivity appeared to be age- and procedure-dependent (Hartley et al., 
1990). Both tests were repeated monthly from age 2 months to age 8 months. In the first 
test, animals were put for two minutes on each of five consecutive days in a circular 
open field whose floor was marked in pie slice-shaped sectors. An observer recorded the 
movements of animals by signing the sectors through which animals passed. The test 
was considered stressful because the short assessment did not allow habituation to the 
environment. CLI animals were significantly more active than Sal at ages 4 and 6 
months, and, as first noted by Mirmiran (Mirmiran et al., 1983), the activity was con-
fined in the periphery of the open field. In the second test, a computerized apparatus 
(Digiscan, Omnitech Electronics®) measured spontaneous motor activity (total activity 
and ambulation) in a plexiglas chamber for 16 minutes on each of five consecutive days. 
This assessment was always performed one week following the open field test. Only 3-
month old CLI rats were significantly more active than Sal rats; any other significant dif-
ferences were not found (Hartley et al., 1990). 
5) In a EEG study, the sleep pattern of 6- and 11-month old rats was observed: 6-
month old CLI rats, but not 11-month old rats, showed in basal conditions a higher REM 
sleep percent, a significantly shorter REM latency, and significantly more REM sleep on-
set periods compared to Sal rats; the abnormalities were mainly in the light period. On 
days 2 and 3 after a 72-h RSD, carried out with the small platform over water method, 
both 6- and, even if in a much lesser degree, 11-month old rats showed a higher REM 
sleep rebound than SAL rats. REM sleep stimulation by RSD was more persistent in CLI 
than in Sal rats (Vogel et al., 1990b). 
6) In several contests, antidepressant treatments improved the symptoms above 
described of CLI rats. RSD, proven by many scientists to ameliorate symptoms of human 
endogenous depression (Adrien, 2002), and imipramine were used as antidepressant 
treatments, even though they clearly act in a different manner. In a test for aggressive 
behavior, the same mentioned in i), CLI rats, treated with both or with either imipramine 
or RSD by small platform over water method, showed an increased shock-induced 
fighting; imipramine significantly reduced hyperactivity of CLI rats in the open field test; 
and both imipramine and RSD improved the sexual performance of CLI rats compared to 
Sal rats (Vogel et al., 1990a). 
Vogel and collaborators interpreted their results as clear signs that clomipramine 
is able to induce in rodents an endogenous depression when administered in the early 
life. Diminished aggressiveness, pleasure-seeking behavior, and sexual activity, as well 
as motor agitation, and REM sleep disturbances are all symptoms of human endogenous 
depression. Vogel brought to light all these aspects in CLI rats and made several interest-
ing considerations. First, hyperactivity shown in the open field test can be hypothesized 
as an overreaction of rats to a stressful situation and the permanence of rats in the pe-
riphery was oriented toward escaping the apparatus, not exploring it. Hyperactivity and 
hyper-responsivity to stress are, again, typical features of depressed patients (Hartley et 
al., 1990). Second, the diminished entity of REM sleep disturbances in basal conditions 
of CLI aged rats suggest that clomipramine plays a self-limited impairment with a spon-
taneous remission after several months (Vogel et al., 1990b). Third, data suggest that 
endogenous depression of CLI rats has a gradual onset, maybe due in part by a delayed, 
life-event independent, long-term increase of REM sleep, and animals show a gradual re-
covery with remission of initial symptoms. These findings confirm that CLI rats are af-
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fected by an endogenous depression more than a reactive depression, is the second one, 
on the other hand, being typical of stress-induced animal models (Vogel et al., 1990b). 
Furthermore, Vogel made some hypotheses on the activity of chronically adminis-
tered antidepressant agents: is brain able to compensate for acute effects of drugs? 
Maybe, unlike the adult brain, the immaturity of a neonate brain does not allow a com-
pensation for the effects of treatment with antidepressant drugs (Vogel et al., 1990a). 
Early life treatment can produce permanent or temporary effects on the functions of a 
brain that is still in a very critically formative stage: brain growth in rodents begins 
antenatally, reaches a peak in the development at post-natal day (PND) 5-10 and contin-
ues until the 3rd-4th post-natal week; synaptogenesis begins before birth, undergoes its 
most extensive development between PND5 and PND20 and goes on until PND40; de-
velopment of neurotransmitter systems occurs up to post-natal 5-6 weeks (Maciag et al., 
2006). So it can be hypothesiszed that neonatal treatment with clomipramine “shakes” a 
developing nervous system that is not able to compensate the insult. As a consequence 
of this, antidepressant drugs could cause a permanent upregulation of post-synaptic re-
ceptors, or an impairment of the normal sleep pattern, or a decrease in aminergic neuro-
transmission: any of these effects is a sufficient condition to produce depression. These 
considerations explain the paradox that administration of antidepressant drugs in adults 
improve depression, while in neonates may produce depression (Vogel et al., 1990a). 
Velazquez-Moctezuma completely disagree with Vogel’s opinion that early ad-
ministration of clomipramine can cause behavioral abnormalities due to RSD or to the 
augmented availability of amines at the synaptic level: neither rats neonatally treated 
with scopolamine, a cholinergic antagonist with a potent suppressive mechanism of 
REM sleep, nor rats treated with idazoxan, a α2-receptor antagonist that can increase 
adrenergic activity, displayed an increase in sexual activity or in time spent in immobili-
ty in the Porsolt’s FST (Velazquez-Moctezuma et al., 1993). 
Many scientists interested in the paradigm of neonatal clomipramine administra-
tion tried to find the explanation for behavioral abnormalities observed in CLI rats by 
measuring the levels of aminergic neurotransmitters. Decreased serotonin levels were 
found in some brain areas of CLI rats, such as frontal cortex, hypothalamus, hippocam-
pus, septum, striatum, and brain stem; further, noradrenaline was found significantly 
decreased in frontal cortex, hippocampus, septum, striatum, brain stem and hypothala-
mus and dopamine was significantly decreased in the hippocampus, frontal cortex, hy-
pothalamus, striatum and brainstem (Vijayakumar and Meti, 1999; Bhagya et al., 2011). 
But a fortnight period of chronic escitalopram treatment between the 2nd and 3rd post-
natal month as antidepressant therapy was able to restore the levels of serotonin, nora-
drenaline and dopamine levels in the hippocampus, frontal cortex, hypothalamus, stria-
tum, and brainstem (Bhagya et al., 2011). 
Andersen and coworkers found in CLI rats different aminergic laterality in some 
brain areas: early clomipramine treatment appears to influence the limbic regions of nu-
cleus accumbens, amygdala, prefrontal cortex and striatum, but not hippocampus, in a 
different degree by shifting laterality of serotonin and dopamine. These effects may play 
a role in the emergence of depression. Furthermore, the perturbation of dopaminergic 
and serotonergic systems with clomipramine treatment may lead to inhibition of a nor-
mal development of brain, since it is known that neurotransmitters act as brain trophic 
factors (Andersen et al., 2002). Not only serotonin levels were influenced by neonatal 
clomipramine treatment, but also serotonin circuitry and neuronal excitability. In CLI 
rats a diminished immunoreactivity, persistent into adulthood, to serotonin transporter 
(SERT) was observed in fiber networks of cortical areas (Maciag et al., 2006). Further-
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more, in CLI rats treated in adulthood with either zimelidine, an SSRI antidepressant, or 
with repeated RSD, serotonergic neurons of nucleus raphe dorsalis showed a lack of re-
sponse to the inhibitory effect of citalopram. Actually, serotonergic neurons of CLI rats 
appeared to be already hyporeactive to citalopram under basal conditions, i.e. without 
zimelidine treatment or RSD; in Sal rats, on the other hand, the firing was reduced as a 
consequence of citalopram administration (Maudhuit et al., 1996). This result raises 
questions about the relationship between serotonergic system’s functionality and ab-
normalities in behavior. 
Clomipramine treatment in the neonatal age was found to affect the levels of oth-
er important substances. Orexin, for example, is a hypothalamic peptide somehow 
linked to serotonin deficiency in depressives and involved in the wake-promoting pro-
cess. Its levels are significantly decreased in young CLI rats (35 days old), but the pattern 
is inverted in the adults (3 or 4 months old). A possible hypothesis to explain this phe-
nomenon is that orexin changes are associated with sleep disturbance typical of depres-
sion: increased levels found in adult CLI rats are compatible with many features of sleep 
associated with depression, since orexin promotes wakefulness and suppresses sleep 
(Feng et al., 2008). 
Also BDNF levels were significantly decreased in the hippocampus of CLI animals 
(Cassano et al., 2006). BDNF is the most diffused trophic factor in the brain, where it 
participates to very important processes such as neuronal growth, long-term potentia-
tion and learning. As described in par. 1.5 altered BDNF levels have been associated in 
humans with the major depressive syndrome. 
An altered sensitivity of central cholinergic system is another one of the possible 
neurochemical correlates of behavioral abnormalities in CLI rats: early-life clomipra-
mine administration enhances the hypothermic response to oxotremorine, an agonist of 
the muscarinic acetylcholine receptor, effect that can be reversed by RSD performed 
with the small platform over water method (Prathiba et al., 2000); furthermore, the sol-
uble form of acetylcholinesterase enzyme was found significantly higher in CLI com-
pared to Sal rats in the hippocampus, but lower in the frontal cortex . Since the choliner-
gic stimulation of brain has been reported to increase REM sleep, the augmentation of 
REM sleep in CLI rats may also be due to increased cholinergic activity (Mavanji and 
Datta, 2002). 
Taken together, all these results about the altered levels of cholinergic-
monoaminergic neurotransmitters, of BDNF, and orexin in different brain regions, sug-
gest that depression-like symptoms of this animal model may be due to a general imbal-
ance of numerous neurochemical correlates. 
A large amount of literature reports about an intricate inter-relationship CRF, 
HPA axis, glucocorticoids, monoamines and mood disorders. It has been hypothesized 
that in depressed patients an altered regulation of the ACTH and, subsequently, an en-
hancement of cortisol levels, may be due to an impaired rhythmicity of the HPA axis 
(Bonilla-Jaime et al., 2010). CLI rats exhibited significantly higher corticosterone levels 
than control group at time-points 0h and 6h after the onset of light phase, but no differ-
ences were detected in the dark phase, thus resulting in a substantial change of the cir-
cadian activity of corticosterone. On the other hand, the levels of corticosterone were re-
stored by a 4-day RSD, performed with the small platform over water method, to values 
comparable to those found in Sal rats (Prathiba et al., 1998) and reduced also by fluoxe-
tine treatment (Bonilla-Jaime et al., 2010). 
Body weight gain was found to be reduced in CLI rats at different ages: during the 
treatment period (Andersen et al., 2002; de Souza et al., 2004), at the end of it (Andersen 
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et al., 2002), and, in the adulthood, at age 3 months (Vijayakumar and Meti, 1999; 
Cassano et al., 2006). In parallel, also food intake at age 3 months was decreased 
(Vijayakumar and Meti, 1999). In depressive patients diminished body weight and food 
intake are common symptoms, thus these data are a further confirmation of the validity 
of the animal model of neonatal clomipramine administration. 
Evaluations of behavioral abnormalities were conducted by many authors, some-
times with results mismatching from those described by Vogel and collaborators. Most 
of the experimentation performed by Vogel used the Sprague-Dawley rat strain, but 
some comparisons were carried out by Vogel himself and by other scientists also in 
Wistar and Long-Evans rats, but without any relevant result that could lead to think 
about a strain-correlated different responsivity to neonatal clomipramine administra-
tion. 
In the FST, many authors confirmed the observation of an increase in immobility 
of CLI rats (Velazquez-Moctezuma et al., 1993; Bhagya et al., 2008; Feng et al., 2008), but 
Yoo and coworkers found no differences among CLI and Sal rats, and imipramine treat-
ment or physical training of CLI rats did not produce any change too (Yoo et al., 2000). 
CLI animals showed no decrease in immobility, but a significant increase in climbing was 
reported by Cassano (Cassano et al., 2006). 
Sexual activity was confirmed to be decreased by many authors (Velazquez-
Moctezuma et al., 1993; Feng et al., 2001; Maciag et al., 2006). Locomotor activity was 
reported to be increased in male CLI rats compared to Sal rats (Andersen et al., 2002; 
Maciag et al., 2006) and also compared to female CLI rats (Andersen et al., 2002), con-
firming hyperactivity as a typical trait of CLI rats. 
The results obtained in the sucrose preference test (SPT) are useful to recognize 
the anhedonic behavior, typical of human endogenous depression. In this animal model 
the SPT performed by other groups had different results from Vogel’s ones: while Vogel 
found no differences between CLI and Sal animals in sucrose consumption, other groups 
observed that CLI rats consumed lower levels of sucrose than Sal rats (Cassano et al., 
2006; Bhagya et al., 2008; Bhagya et al., 2011), but chronic escitalopram treatment of 
CLI rats restored sucrose preference (Bhagya et al., 2011).. 
Further behavioral tests were conducted to investigate the following issues: 
1. anxiety trait: in the elevated plus maze (EPM) test contradictory results were ob-
tained. Andersen observed that CLI rats, at PDN70, spent a significantly lesser 
time in the open arms compared to Sal rats (Andersen et al., 2002), while Cassano 
found the opposite result at PND90 (Cassano et al., 2006). In a more recent work, 
Andersen confirmed the high anxiety trait of CLI rats in the EPM test, with the ob-
servation that CLI rats spent more time than Sal rats in the closed arms of the in-
strument, and, in another test, the marble burying test, CLI rats buried more nov-
el objects than Sal rats (Andersen et al., 2010); 
2. cognitive impairment: in the Morris water maze (Cassano et al., 2006) and in the 
radial arm maze test (Bhagya et al., 2008; Bhagya et al., 2011), CLI rats showed a 
spatial memory impairment, and chronic escitalopram treatment significantly re-
stored it to scores typical of Sal rats (Bhagya et al., 2008; Bhagya et al., 2011). 
3. somatic growth, maturation and development of sensory-motor reflex: the tests, 
performed in neonatally citalopram treated rats, showed that development of 
these parameters was delayed (Deiro et al., 2004). De Souza and coworkers found 
that CLI rats showed an alteration of some physical developmental parameters 
such as reduced body growth, reduced growth of the antero-posterior and latero-
The clomipramine model of depression in the rat  29 
lateral axis of the body, reduced tail and head sizes were recorded at specific 
PNDs during the treatment period. Clomipramine treatment did not alter the 
maturation of any of the already assessed physical characteristics such as ear un-
folding, auditory conduit opening, eruption of the lower incisors, and eyes open-
ing. Furthermore, clomipramine treatment did not significantly alter the tem-
poral pattern of onset of the tested reflexes (righting, vibrissa placing, cliff avoid-
ance, negative geotaxis, auditory startle, and free-fall righting) (de Souza et al., 
2004). 
Recently, Andersen and coworkers proposed that the neonatal clomipramine 
administration is able to produce a model of OCD, a condition mediated by specific 
cortico-striatal- thalamic-cortical circuits and characterized by anxiety, perseveration 
and , behavioral inflexibility, and working memory impairments (Stein et al., 2000; 
Andersen et al., 2010). According to Andersen, CLI rats present behavioral characteris-
tics consistent with an OCD-like profile in humans: the anxiety-like behavior was as-
sessed with the EPM test and the murble burying task (already mentioned), while the 
perseverative-like behavior was observed with the simple spontaneous alternation task; 
an impairment in reversing direction and in a working memory task suggested a certain 
degree of learning impairment (Andersen et al., 2010). 
Interestingly, Andersen and collaborators argued that the neonatal clomipramine 
paradigm reproduced in their labs was an animal model of depression in a previous 
work (Andersen et al., 2002), reporting much evidence of it. We noticed that the period 
and duration of treatment differ, even if slightly, from the one reported in the descrip-
tion of the OCD model. It is known that the post-natal period is a very important phase 
and that each of the first post-natal weeks is characterized by the formation of specific 
structures and development of specific functions in the brain. Thus, we wonder if the 
slight difference in the treatment period could be crucial for the determination of either 
a syndrome or the other. It is hard to believe it, since many authors, who defined CLI rats 
affected by an endogenous depression, treated animals in different periods (but always 
in the first post-natal 4 weeks) with different durations, administration routes (subcuta-
neous or intra-peritoneal) and doses of clomipramine (from 15 to 30 mg/kg), and the 
results were comparable from an author to another. 
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2 Study 1 – Neurogenesis in clomipramine-treated rats  
2.1 Introduction 
As already described in section 1.2.1, hippocampal neurogenesis has been shown 
to be affected in animal models of depression, but data from neurogenesis studies have 
never been reported by any author who investigated this animal model of depression.  
Neurogenesis rate was studied with the employment of a double immunohisto-
chemistry and the markers chosen were 5’-bromo-2’-deoxyuridine (BrdU) and 
doublecortin. BrdU is one of the most used markers of newly generated cells and it is an 
analogue of thymidine which is incorporated in the DNA of proliferating cells during the 
S-phase of the cell cycle. BrdU staining conveys the total cell proliferation rate, but the 
identification of newly born neurons in the dentate gyrus of the hippocampus requires a 
specific additional marker, that does not label non-neuronal cells and is able to label all 
types of neurons. Double immunostaining with BrdU and DCX was necessary to demon-
strate that DCX-labeled (DCX+) cells were clearly the newly generated neurons since 
DCX is a cytoplasmic microtubule-associated protein involved in two important phases 
of neuronal development, migration and differentiation (Rao and Shetty, 2004). A very 
detailed description of a range of morphologies of DCX+ cells was provided by Plumpe 
(Plumpe et al., 2006), who divided cells expressing DCX in 6 categories, reflecting a con-
tinuum, according to the presence and the shape of apical dendrites. DCX is transiently 
expressed during a period lasting approximately 3-4 weeks, and it is not present in ma-
ture neurons. The period of expression extends from a proliferating progenitor cell 
stage, to a postmitotic phase in which cells present long dendrites (Plumpe et al., 2006).  
Following a specific protocol of BrdU administration and performing a double 
immunostaining with BrdU and DCX, it is possible to study the influence of a long-term 
or short-term stimuli on the birth and maturation of new neurons.  
As mentioned in section 1.2.1, several experimental conditions have been ob-
served to affect proliferation and survival of newly generated neurons in the rodent hip-
pocampus, either positively, such as enriched environment, physical exercise, and learn-
ing, or negatively, like stress and glucocorticoids. These observations suggest a role of 
neurogenesis in the adaptation to new environmental and physiological conditions and 
in the regulation of cognitive functions and behavior, also in mood disorders such as de-
pression (Meerlo et al., 2009).  SD has been long studied as a factor influencing neuro-
genesis: it has been shown that short (<1 day) SD does not strongly affect neurogenesis, 
on the contrary it can even lead to an increase of it (Grassi Zucconi et al., 2006), but it 
significantly suppresses cell proliferation if it is prolonged (Meerlo et al., 2009). The re-
peatedly reported clinical data about the antidepressant effect, even if transient, of one-
night SD on patients (Adrien, 2002) induced us to investigate on a possible role of SD on 
mood and hypothesize a correlation with changes in neurogenesis rate. Enforcing wake-
fulness in laboratory animals can be carried out with several methods, such as gentle 
handling, forced locomotion in a slowly rotating drum, forced locomotion on a treadmill, 
or the small platform over water method (Meerlo et al., 2009). Each method has its own 
imperfections unrelated to sleep loss, but they all can be avoided with some devices 
(Meerlo et al., 2009). The gentle handling method was chosen among the several meth-
ods in order to induce a total SD with a procedure aimed at possibly excluding confound-
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ing variables known to affect neurogenesis, such as stress, physical exercise and en-
riched environment (Grassi Zucconi et al., 2006).  
Behavioral assessment with the FST was part of a set of observations already de-
scribed in literature: this test was necessary to assess that the procedure of drug admin-
istration reproduced a behavioral model of the neonatal clomipramine treatment com-
parable with data reported in literature. FST was first introduced by Porsolt (Porsolt et 
al., 1977) as a tool to measure the antidepressant efficacy of drugs in reducing the des-
pair behavior of rodents when put in a helplessness situation, such as a cylinder full of 
water from which animals cannot escape. Animals basically struggle during the first se-
conds of the test, but then they give up and slow down or stop their movings in water 
doing nothing but floating. It has been repeatedly observed that antidepressant agents 
are able to reduce time spent in immobility of rodents in the FST (Cryan et al., 2005). 
The first experiment performed was designed to investigate: 
• despair behavior in a helplessness paradigm; 
• hippocampal neurogenesis in basal conditions and effects of a short-term SD on 
it;  
• possible morphological changes in dendritic arborization of hippocampal granule 
cells due to early-life clomipramine treatment. 
 
2.2 Materials and methods 
2.2.1 Animals 
Pregnant Sprague-Dawley rats (Harlan), were put on a 12:12h light/dark cycle 
(lights on at 8:00 am) and maintained at room temperature (20±2°C) with food and wa-
ter ad libitum. At birth, pup rats were left with their own dams and never separated from 
them a part for 5 minutes twice a day, each day, until PND4, during which they were ha-
bituated to be handled by experimenters. 
2.2.2 Treatment  
From post-natal day (PND) 5 until PND21 animals were intra-peritoneally (i.p.) 
injected, twice daily, with either a 20mg/kg solution of clomipramine (Sigma-Aldrich) or 
an equivalent volume of 0.9% sodium chloride solution (Fresenius Kabi). During the pe-
riod of treatment, animals were weighed daily, in order to check the body growth rate. 
After weaning, animals were divided by their own dams and housed singularly. After a 
period of habituation, rats underwent behavioral assessment. 
2.2.3 Forced swim test  
At 2 months of age, depressed behavior was tested with the forced swim test. The 
procedure adopted differs from the classical Porsolt test (Porsolt et al., 1977) for the use 
of a large cylindrical pool (Ø 132 cm) instead of the standard, 30 cm-wide, cylinder. The 
subjects’ motor activity was video-recorded and analyzed with the help of the 
Ethovision® software, whose output was the calculation of the amount of time spent in 
swimming, struggling, as an attempt to escape from the cylinder, and distance moved 
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(m). The assessment for each animal was performed over  two days and consisted of a 
15-minute training on day 1 and a 5-minute test on day 2.  
2.2.4 Sleep deprivation  
At 4 months of age, animals entered the final stage of the protocol.  
Animals were divided in two groups: a group of animals underwent 10 hours of 
sleep deprivation by gentle handling, starting at the beginning of their circadian resting 
phase (8:00 am, lights on), while another group remained undisturbed. During the gen-
tle handling procedure, animals were kept awake by tapping on or gently shaking the 
cage, touching their tails or whiskers, gently pushing them, etc. (Grassi Zucconi et al., 
2006). 
2.2.5 BrdU injections 
All animals, both sleep deprived and non-sleep deprived, received two injections 
of BrdU (100 mg/kg i.p.; Sigma-Aldrich), four and two hours before the end of the sleep 
deprivation period. At the end of sleep deprivation (6:00 pm) all animals underwent the 
perfusion protocol.   
2.2.6 Perfusion and brain processing 
Animals were deeply anesthetized with pentobarbital (80 mg/kg i.p.), 
transcardially perfused with a cold NaCl 0.9% solution (Fresenius Kabi) followed by ice-
cold 4% paraformaldehyde (Sigma-Aldrich) in PBS. Brains were removed, post-fixed 
overnight in the same paraformaldehyde solution, and cryoprotected in a 30% sucrose 
solution until they sank. Brains were subsequently frozen at the microtome and cut in 
40 µm-thick coronal sections, which were preserved in PBS 0.1M with 0.1% NaN3 until 
histological processing.  
2.2.7 BrdU-DCX immunohistochemistry 
Sections from 24 animals, 12 males and 12 females, each sex group comprehend-
ing 6 sleep-deprived and 6 control animals, were first processed for BrdU immunohisto-
chemistry and then stained for the DCX protein. All washes were performed in 0.01M 
PBS containing 0.1% of Triton X-100.  
BrdU immunohistochemistry. After incubation in 0.75% H2O2 in 0.1M PBS for 20 
min for peroxidase inactivation and DNA denaturation with an incubation in 2N HCl in 
0.1M PBS for 30min at 37˚C followed by 10 minutes in borate buffer (pH 8.5), sections 
were blocked in 3% BSA + 0.3% Triton X-100 in PBS for 90min. Then sections were in-
cubated overnight with a monoclonal mouse anti-BrdU (NCL-BrdU, Novocastra, 103014; 
1:500) diluted in PBS containing 1% BSA+ 0.3% Triton X-100 at 4˚C. Incubation in sec-
ondary antibody (biotinylated goat anti-mouse IgGs; 1:200) diluted in PBS containing 
1%BSA+0.3% Triton X-100 lasted 2h at room temperature. Then the staining was devel-
oped with the ABC kit (incubation for 1h at RT) followed by an incubation in 0.1M PBS 
containing 0.05% NiCl + 0.025% DAB +0.003% H2O2 for 5 min. 
DCX immunohistochemistry. After incubation in 0.75% H2O2 in 0.1M PBS for 20 
min for peroxidase inactivation, sections were blocked in 5% BSA + 0.3% Triton X-100 
in PBS for 90min. Then sections were incubated overnight with a polyclonal goat anti-
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DCX (Santa Cruz; 1:500) diluted in PBS containing 1% BSA+ 0.2% Triton X-100 over-
night at room temperature; incubation in secondary antibody (biotinylated horse anti-
goat IgGs; 1:200) diluted in PBS containing 1% BSA+ 0.2% Triton X-100 was performed 
for 2h at room temperature. Then the staining was developed with the ABC kit (incuba-
tion for 1h at RT) followed by an incubation in 0.1M PBS containing 0.05% DAB + 0.03% 
H2O2 for 5 min. 
2.2.8 Cell counts 
Stained sections were examined with a 40x objective under a light microscope. 
Counts of labeled cells were performed in the subgranular zone of the entire extent of 
dentate gyrus by visual inspection in 4 evenly spaced sections for each animal, approxi-
mately beginning at Bregma -2.45 and ending at Bregma -5.65 of the hippocampus, ac-
cording to the stereotaxic coordinates reported by Paxinos and Watson (Paxinos and 
Watson, 2005). The total number of BrdU-labeled (BrdU+), BrdU/DCX-labeled 
(BrdU/DCX+) and DCX-labeled (DCX+) cells was acquired by the same operator under 
sex- and treatment-blind conditions. Furthermore, newborn cells, defined by Plumpe as 
granule cells with very short or no processes (Plumpe et al., 2006), were identified and 
counted in order to evaluate SD effect on proliferation rate. 
2.2.9 Cell morphology 
Morphological analyses were conducted on a sample of DCX-labeled cells (72 
neurons, 3 per animal) to investigate dendritic arborization rate, cell body size (perime-
ter and area), number of dendritic nodes, and total dendritic length.  Well-differentiated 
DCX-labeled neurons chosen for the analysis exhibited dendrites with the following fea-
tures: (i) they were vertically orientated and extended into the molecular layer of the 
dentate gyrus; (ii) not cut off in the immediate proximity to the soma; and (iii) with min-
imal overlap with the dendrites of close cells to avoid ambiguous tracing. 
The analysis was carried out with a 100x objective, using a semiautomatic neuron 
tracing system (Neurolucida 8.0, Microbrightfield®), linked to a Nikon motorized micro-
scope. Cells tracings were acquired with Neurolucida’s Autoneuron module and the 
three-dimensional analysis of reconstructed neurons was performed by using the 
Neuroexplorer software (Microbrightfield®) and choosing the Branched structure analy-
sis to determine all the parameters listed above.  
2.3 Results 
2.3.1 Body weight 
Animals’ body weights measured in the morning of each day of the treatment pe-
riod were chosen for the analysis. The graph in Fig. 2.1 clearly shows how clomipramine 
treatment influenced the rate of body growth: in CLI animals body weight was signifi-
cantly reduced compared to SAL animals (Repeated measures analysis, PND as a repeat-
ed factor, F(1,53) =29.670, p<0.001).  
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Fig. 2.1. Body growth rate of CLI and SAL rats during the 17-day period of treatment. 
2.3.2 Behavioral assessment with the forced swim test 
In Fig. 2.2, graph a) represents time spent in immobility during the 5-minute test, 
while graph b) shows distance moved by animals during the test. None of the parame-
ters analyzed in the performance of the FST showed significant differences due to either 
treatment or sex. 
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Fig. 2.2. a) time spent in immobility and b) distance moved by animals during the FST 
2.3.3 BrdU+ and DCX+ cell counts  
Graphs reported in Fig. 2.3 show total BrdU+ (a) and total DCX+ (b) cells counted 
in the dentate gyrus of 4 evenly spaced sections of hippocampus. Given the sample size 
and the within group variance, we cannot draw conclusions on between-group differ-
ences . An observation, that can be made by looking at the graphs in Fig. 2.3, is that fe-
males show a higher number of both BrdU+ and DCX+ cells, in spite of the variability of 
cell counts.  
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Fig. 2.3 - a) Total BrdU+ cell counts: all cells that appeared immunostained with BrdU, double labeled 
cells included, were considered in the counting; b) total DCX+ cell counts: the cells that appeared 
double-labeled represent new neurons. In both analyses, females showed a higher number of cells. 
2.3.4 Cell morphology 
Representative reconstructions performed with the Neurolucida software are re-
ported in Fig. 2.4, together with microphotographs of the plotted cells. 
 
Fig. 2.4 - Representative pictures from neuron reconstruction with Neurolucida: a) and c) are microphoto-
graphs of DCX+ neurons from, respectively, a Sal and a CLI animal, and b) and d) are their reconstructions 
with the Neuroexplorer tool of the Neurolucida software. 
 
a 
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d 
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The graph in Fig. 2.5 shows, for each animal, the total dendrite length of each hip-
pocampal granule cell reconstructed with the Neurolucida software. Cells showed a 
great variability in the total dendrite length not only within the same experimental 
group, but also within the same animal. The low number of cells analyzed showed a high 
variability in the features considered, and, for this reason, a statistical evaluation of sex 
and treatment effects was not performed. A larger population of reconstructed cells is 
needed to make a reliable statistical analysis to estimate sex and treatment effects.  
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Fig. 2.5 - Total dendrite length of cells analyzed with the Neurolucida software.  
We could appreciate qualitative differences in the dendritic arborization between 
CLI and SAL animals: newly generated neurons in the SAL group (Fig. 2.6A) appear to 
have longer processes that extend vertically and transverse both hippocampal granule 
cell layer and the inner region of the molecular layer, while neurons of the CLI group 
(Errore. L'origine riferimento non è stata trovata.B) were more irregular and ap-
peared dystrophic, with convoluted helical-shaped processes. 
 
Fig. 2.6 - Microphotographs of the BrdU/DCX immunostaining from representative A) Sal and B) CLI ani-
mals respectively: dendrites of the CLI animal appear shorter and less arborized than those of SAL animal. 
Some dystrophic features of dendrites are visible in the CLI animal, but not in the SAL animal. 
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2.4 Conclusions 
These preliminary data from the investigation of the relationships between de-
pression, sleep deprivation, and neurogenesis offered interesting clues to the future di-
rections of the study, but also point out clear limitations that need to be addressed. 
Preliminary behavioral results showed the need to collect more data, given the 
variability found in the studied groups. In this respect, the employment of different 
tasks, such as sucrose preference test, activity tests, and food intake monitoring, became 
necessary to better characterize symptoms of depression in our model.  
Sleep deprivation effect on hippocampal cell proliferation was not consistently 
demonstrated, but with regard to neurogenesis and morphological studies, the popula-
tion of animals considered in each group was very low and the variability was too high 
to get statistical significance.  
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3 Study 2 - Behavioral, imaging, and neurochemical char-
acterization of the neonatal clomipramine model in the 
young and aging rat 
3.1 Introduction  
Results from Experiment 1 gave useful indications on the need of a deeper behav-
ioral characterization. In Experiment 2 behavioral investigation included the classical 
Porsolt’s FST for the measure of despair behavior (Porsolt et al., 1977) and by a further 
test to investigate anhedonic behavior, the sucrose preference test (SPT).  SPT  is a re-
ward-base test for depression which measures a rat’s appetite for a highly palatable su-
crose solution. A decrease of sucrose consumption in a limited access paradigm has been 
long used to determine hedonic deficits. Sucrose consumption can be measured as abso-
lute intake or percentage of consumed sucrose solution over the total amount of liquid 
drunk in the 2h-test following a stressful period of food and liquid deprivation. Some au-
thors consider SPT not to be a convincing measure of anhedonia because sucrose intake 
can be affected by many factors not related to the hedonic state of the animals,  such as 
prolonged effects of stress procedures, food and water deprivation, and reduced meta-
bolic need of sucrose intake due to loss of body weight (Strekalova et al., 2004). Alt-
hough all these negative opinions, nowadays SPT is largely accepted as a tool to investi-
gate the anhedonic behavior in animal models of depression. 
In order to investigate if volume changes of several brain regions observed in de-
pressed patients  were evident also in animals, a brain imaging analysis was performed. 
A MRI study showed in olfactory bulbectomized rats, compared to sham controls, signif-
icant volumetric changes such as decreased volumes of  frontal cortex and amygdala and 
an enlargement of lateral ventricles, but no changes in the volume of hippocampus 
(Wrynn et al., 2000), that is one of the brain regions found to be reduced in humans 
(Bremner et al., 2000; Sheline, 2000; MacQueen et al., 2003; Neumeister et al., 2005).  A 
further study  performed on the chronic mild stress rat model of depression with tridi-
mensional MRI technique confirmed the absence of volumetric differences in the meas-
ure of hippocampal extent among stressed animals and controls (Delgado y Palacios et 
al., 2011). On the other hand, rats chronically restrained for 6h/day for 21 consecutive 
days showed a reduction in hippocampal volume compared to a measurement per-
formed before the stress procedure (Lee et al., 2009). This result may suggest that the 
stress procedure adopted to induce depression could be determinant in provoking brain 
volume changes. None have described about brain regions measurements in our model, 
so we performed the analysis on several regions involved in the pathophysiology of de-
pression.  
The increasing evidence of the role for BDNF in the mechanism and treatment of 
depression has been reported by many authors in both clinical and preclinical studies, in 
particular in animal models of stress-induced depression. Determination of brain BDNF 
levels in the rat hippocampus has been already performed in this animal model of de-
pression through Western blot analysis: CLI animals showed a reduction of BDNF com-
pared to SaL animals (Cassano et al., 2006).  The confirmation of this result with an in-
vestigation of BDNF levels in hippocampus and in cortex was performed with ELISA 
technique.  
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Glial cells are the most abundant cells within the central nervous system and are 
represented by three different types of cells: oligodendrocytes, microglia, and astro-
cytes. We focused our attention on astrocytes, the most abundant glial cells constituting  
about one third of the mass of the brain. They have the function to support neurons, me-
tabolize neurotransmitters, maintain ion homeostasis in the extracellular tissue, regu-
late neuronal migration, secrete growth factors and participate in the immune and in-
flammatory responses, and in the constitution of the BBB (Fuchs et al., 2004); moreover, 
it has been hypothesized that astrocytes may regulate formation, maturation, and 
maintenance of synapses through a dynamic communication with neurons (Slezak and 
Pfrieger, 2003). As already said, significant decrements in the hippocampal volume of 
depressed patients was repeatedly reported (Stockmeier et al., 2004) and 
histopathological correlates of this evidence included loss of glial cells, reduction in syn-
apses, increase in neuronal density, and reduction in neuronal size (Drevets et al., 2008).  
Furthermore, post-mortem studies on brains of depressed patients demonstrated al-
tered expression of glial fibrillary associated protein  in prefrontal cortex (GFAP) (Si et 
al., 2004). In laboratory animals, GFAP mRNA expression was decreased in the prefron-
tal cortex of chronic unpredictable stress model of depression, and reversed or prevent-
ed by chronic riluzole treatment (Banasr et al., 2010), and decreases in GFAP 
immunostaining and number of GFAP-labeled cells in the hippocampus were reported 
after chronic psychosocial stress (Czeh et al., 2006). In Wistar-Kyoto rats, a genetic 
model of anxiety and depression, Gosselin and coworkers found, compared to control 
Sprague-Dawley rats, a lower GFAP immunoreactivity in the infralimbic, prelimbic, cin-
gulate cortex, basolateral amygdala and hippocampal CA3 and dentate gyrus regions 
(Gosselin et al., 2009). These results suggest a glial pathology correlated with depression 
(Banasr et al., 2010) but they do not give any information about the alteration of glial 
function or about a possible correlation with behavioral impairments. 
In many animal models of depression, sex differences were reported (Dalla et al., 
2010), but there is no literature about this issue for the neonatal clomipramine model. 
Another important factor that we examined was aging: Vogel reported about a remission 
of some of the effects induced by neonatal clomipramine administration late in life 
(Vogel et al., 1990a). Herein, behavioral and neurochemical effects of age were investi-
gated in three different age groups of rats. 
Experiment 2 was aimed at a deeper characterization of the neonatal clomipra-
mine model of depression in a larger cohort of animals with the purposes of: 
• investigating abnormalities associated with depression: 
o weight changes 
o anhedonia  
o behavioral despair 
o brain volume changes 
o BDNF levels 
• studying neural plasticity: 
o hippocampal neurogenesis  
o astrocytic density 
o neuron morphology 
• investigating any effects of sex and age. 
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3.2 Materials and methods 
3.2.1 Animals 
All animals were treated with the same procedures adopted in Experiment 1, de-
scribed in section 2.2.1. 
3.2.2 Treatment 
The period, the route of administration and the doses were the same as those de-
scribed in section 2.2.2. 
3.2.3 Experimental procedures and groups of animals 
The diagram below (Fig. 3.1) shows the experimental procedures to which 3 
groups of animals were subjected. The three groups of animals differed for the age to 
which they were tested in behavioral paradigms and successively sacrificed to allow his-
tological studies on brain tissue.  
 
 
Fig. 3.1 - Time-line of the experimental procedures of the three age groups of animals. 
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3.2.4 Behavioral assessment 
3.2.4.1 Forced swim test  
According to the largely validated protocol established for the first time by 
Porsolt (Porsolt et al., 1977), the animals were placed for 5 minutes in an acrylic glass 
cylinder (h 50cm x Ø 30cm) filled up to 30 cm with lukewarm water, with no possibility 
to escape. A 15-minute training session was performed 24 hours before the test session. 
Both training and test sessions were performed during the light phase and recorded by a 
video camera; video footage was analyzed by a rater unaware of the treatment condition 
in order to determine time spent in immobility, swimming, climbing, and diving. A rat 
was considered immobile if the only movements that it made were aimed at keeping the 
head above the water with the barycenter of animal body essentially in the same posi-
tion; climbing was judged as an active attempt of stepping over the walls of the cylinder, 
with forceful thrashing movements and rat forelimbs  against the walls; active swim-
ming was judged when animals moved all 4 paws causing a continuous movement of the 
body barycentre; diving was performed by rats swimming below the water towards the 
bottom of the cylinder. 
All animals from the three age groups were tested in order to make an age com-
parison of the performances. 
3.2.4.2 Sucrose preference test (SPT 
The sucrose preference test (SPT) is largely adopted to measure anhedonia, i.e. 
the incapacity to experience pleasure in situations that prelude to pleasure, like sleep-
ing, eating, social relations, and sexual activity. Anhedonia is a key symptom of human 
depression. 
In this paradigm, rats’ responsiveness to reward is tested by offering them a solu-
tion of 1% sucrose and tap water. The protocol we used was the same as described by 
Bhagya and coworkers (Bhagya et al., 2008), and it consisted of three steps: 
• a 48-hour training session during which rats had free access to food and to both 
plain water and a sucrose solution; every 24 h, the position of the 2 bottles was 
swapped to prevent position preference and bottles were weighed in order to 
quantify liquid consumption; 
• an 18-hour period, at the end of the training session, during which rats were de-
prived of food and liquid; 
• a 2-hour test session, after the period of deprivation, during which rats were al-
lowed free access to both water and sucrose solution, but not food. Again, liquid 
consumption was determined. 
All animals belonging to three age groups were tested and total liquid intake and 
percentage of sucrose consumed over total liquid intake were analyzed in both habitua-
tion and test phases. 
3.2.5 Brain MRI volumetry 
Volumetric analysis was performed using non-invasive magnetic resonance imag-
ing (MRI), a technique that allows measurements in vivo. Table 3.1 shows the list of the 
38 animals selected for the analysis. 
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Group Sex Treatment group 
Number of 
animals 
Young 
Female 
CLI 5 
Sal 5 
Male 
CLI 8 
Sal 8 
Aged Female 
CLI 7 
Sal 5 
Table 3.1 - List of the animals used for the MRI analysis of volumetry of total brain and several brain 
regions. Middle-aged animals were excluded from the analysis. 
Animals were anesthetized by mechanical ventilation of a mixture of oxygen con-
taining 2% of isofluorane and placed in a custom-made head holder with an integrated 
surface head coil. Body temperature was monitored throughout the scan. Scans were 
performed on a 4.7T Bruker Biospec tomograph (Bruker, Germany) equipped  with a 
33cm bore magnet (Oxford ltd, UK). A tripilot image was used for reproducible anatomi-
cal orientation of 18 coronal rapid-acquisition relaxation enhancement (RARE) images 
(TR=4000 ms, TE = 19.4 ms, TEeff 43.8 ms, RARE factor four, six averages, spatial reso-
lution 0.068 x 0.068 x 0.75 mm3, 0.75mm slice thickness with 0.1 mm gap, field-of-view 
3.5 x 3.5 cm2, matrix 512 x 384) which were positioned perpendicular to a line connect-
ing the superior end of the olfactory bulb with the superior end of the cerebellum ac-
cording to Wolf (Wolf et al., 2002). Using an in-house developed, Matlab based, image 
analysis program, the regions of interest (Wiegers et al.) were manually outlined on the 
images by a rater who is familiar with basic rat neuroanatomy and using a standard rat 
brain atlas (Paxinos and Watson, 1998) for reference. The extent of the hippocampus 
was traced on five consecutive slices in the individual animals. The most anterior hippo-
campal slice included corresponded to a level approximately -2.16 mm posterior to 
bregma, the most posterior hippocampal slice included corresponded to -6.00 mm pos-
terior to bregma. The delineation of the mPFC started at the first appearance of the for-
ceps minor of the corpus callosum (approximately 4.20 mm from Bregma) and ended at 
approximately 0.96 mm from Bregma, including prelimbic cortex, infralimbic cortex ar-
eas and anterior cingulated cortex areas 1 and 2. In more details, the medial prefrontal 
cortex was measured in 5 consecutive slices. Lateral and third ventricles were delineat-
ed in 11 consecutive slices. The brain volume was outlined on 14 consecutive slices, 
starting at 4.68 mm from the Bregma rostrally and ending at -6.36 mm from the Bregma 
caudally. Volumes were calculated by multiplying the number of pixels by the pixel size 
(0,0036992 mm3/pixel) accounting for the interslice gap and were given in mm3.  
3.2.6 BDNF analysis 
A group of 10 males, 5 CLI and 5 Sal rats, were selected from the young group of 
animals. They were deeply anesthetized with pentobarbital, their brains were removed 
and hippocampus ant total cortex were rapidly taken out and at once stored at -80°C un-
til the time of analysis. 
Tissues were homogenized by using a dounce homogeniser  in 10 volumes 
(weight/volume) of extraction buffer (0.01 M Tris–HCl buffer, pH 7.4, containing 1 mM 
EDTA, and a protease inhibitor cocktail (Sigma Aldrich), left at 4°C for 10 minutes and 
centrifuged at 4 °C for 10 min at 14,000 rpm. Supernatants were recovered, aliquoted 
and stored at -80°C. Protein contents of lysate were determined with Bio-Rad Protein 
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Assay (Bio-Rad Laboratories, Milan, Italy) using bovine serum albumin as a standard 
(Sigma Aldrich).BDNF levels were measured by anti-human BDNF sandwich-ELISA ac-
cording to the manufacturer’s specifications (R&D Systems), being the mature BDNF 
protein  100% conserved among humans and rats (Maisonpierre et al., 1991). Briefly, 
half-area microtiter plates (Costar) were coated with capture anti-BDNF antibody by an 
overnight incubation at RT. After blocking of non-specific binding with Reagent Diluent 
(PBS containing 1% BSA) for 1h at RT, plates were incubated with the samples diluted in 
Reagent Diluent (dilution 1:8 of samples from hippocampus, 1:2 from cortex, according 
to Elfving (Elfving et al., 2010)) or with standard curve ranging from 47 to 1500 pg/ml 
for 2 h at RT with shaking. Then, the antigen was incubated with the biotinylated anti-
BDNF detection antibody for 2 h at RT with shaking and with steptavidin-HRP for 20 
min at RT. The addition of  3,3’,5,5’-tetramethylbenzidine started the colour reaction. 
The reaction was stopped 20 min later with 1M HCL solution, and the absorbance was 
immediately measured at 450nm (EL 800 Universal Microplate reader, Bio-Tek instru-
ments, Inc). BDNF concentrations were determined from the regression line for the 
BDNF standard and expressed as ng BDNF/mg total proteins. All assays were performed 
in duplicate which were averaged for statistical comparisons.  
3.2.7 BrdU injections 
All animals, received two i.p. injections of BrdU (100 mg/kg, Sigma-Aldrich), four 
and two hours before sacrifice.  
3.2.8 Perfusion and brain processing 
All animals were subjected to the same procedures described in section 2.2.6. 
3.2.9 BrdU-DCX immunohistochemistry and cell counting 
Brain sections from the young and aged group were processed for the double 
immunohistochemistry with BrdU and DCX markers as described in section 2.2.7.  
3.2.10 Cell counting 
Cell counts were performed as described in section 2.2.8. 
3.2.11 Cell morphology 
As described previously (section 2.2.9), morphological analyses were conducted 
to investigate dendritic arborization rate, cell body size (perimeter and area), number of 
dendritic nodes, and total dendritic length of DCX+ granule cells of the subgranular zone 
of the dentate gyrus of hippocampus. In this experiment, not only the Branches Struc-
ture analysis was performed, but also the concentric spheres analysis of Sholl,  in order 
to measure branching pattern of the dendritic growth away from the soma (Arisi and 
Garcia-Cairasco, 2007). In the basic procedure, the number of intersections of dendritic 
processes with rings of increasing radii centred in the cell soma are counted. The Sholl 
profile of a cell is then obtained by plotting the number of intersections versus the radial 
distance from the cell soma. The morphological study was performed only on neurons of 
young animals, chosen with the same criteria previously reported. 
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3.2.12 Glial fibrillary acidic protein (GFAP) immunohistochemistry and 
densitometric analysis of astrocytic immunosignal  
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein exclu-
sively found in the cytoskeleton of astrocytes, and is therefore used as a specific marker 
of these cells. Brain sections from young and aged animals were processed for GFAP 
immunoreactivity (GFAP i-r) measured as optical density (OD).  
GFAP immunostaining: after incubation in 1% H2O2 in 0.1M PBS for 20 min for 
peroxidase inactivation, sections were blocked in 5% BSA + 0.3% Triton X-100 in PBS 
for 90min. Then sections were incubated overnight with a polyclonal rabbit anti-GFAP 
(DAKO; 1:500) diluted in PBS containing 1% BSA+ 0.2% Triton X-100 overnight at 4°C; 
incubation in secondary antibody (biotinylated horse anti-rabbit IgGs; 1:200) diluted in 
PBS containing 1% BSA + 0.2% Triton X-100 was performed for 2h at room tempera-
ture. Then the staining was developed with the ABC kit (incubation for 1h at RT) fol-
lowed by an incubation in 0.1M PBS containing 0.05% DAB + 0.03% H2O2 for 3-5 min. All 
the washes were done with 0.01M PBS containing 0.1% of Triton X-100. 
Densitometry: photographs at high magnification were taken with a digital cam-
era connected to a microscope (objective 40X ) and background signal (non specific 
GFAP i-r signal) was calculated for each frame chosen from the areas of interest (Table 
3.2) in coronal sections selected between rostro-caudal levels -2.88 mm to +2.2 mm 
(relative to Bregma, Paxinos and Watson, 1998). GFAP i-r values were normalized to OD 
values with the following formula:  
1-(ODx/ODb) 
where ODx is the OD of the brain area considered, and ODb is the OD of the back-
ground measured in the same section of the brain area analyzed. 
 
Brain area frames per side per animal Bregma 
Cingulate cortex 4 0.00 
Motor cortex 2 0.00 
Parietal cortex 2 -3.48 
Hippocampal hilus 4 -3.48 
Hippocampal CA2 4 -3.48 
Table 3.2 - Number of frames selected from the brain areas of interest according to Paxinos and Wat-
son, 1998. 
3.3 Results 
3.3.1 Body weight monitoring 
Each animal’s body weight was monitored twice a day until the end of the treat-
ment period.  
In the chart below (Fig. 3.2) the body weight of a subgroup of all CLI and Sal ani-
mals is reported as a function of time: a treatment effect was observed, with CLI animals 
showing a significant decrease in body growth rate compared to Sal animals during the 
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period of treatment (Repeated measures ANOVA with F (1,61) = 38.91, p<0.0001). No sex 
differences in body growth rate were observed during the period of treatment. 
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Fig. 3.2 - Body growth rate during the 17-day period of treatment. 
3.3.2 Behavioral assessment 
3.3.2.1 Forced swim test  
3.3.2.1.1 Treatment and sex correlation in the young group  
The chart below (Fig. 3.3) reports the amount of time spent in immobility by 
young animals for each minute of the 5-min test. The graph shows that females, and in 
particular the group of CLI females, spent more time in immobility compared to males 
already at the first minute of the test, while the amount of time spent in immobility is the 
same at the end of the test. A Repeated Measures ANOVA showed a significant effect of 
time (F (4,136) =60.597, p<0.0001) and of sex (F (1,37) =10.579, p<0.05), indicating that, 
during the 5-minute test, immobility time progressively increases for all the animals, 
and that females showed greater immobility than males. Furthermore, a significant in-
teraction effect time*sex*treatment (F (4,136) = 2.808, p<0.05) was shown, with CLI fe-
male rats spending more time in immobility than the other groups of animals. 
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Fig. 3.3 - Immobility during FST in young animals. The chart reports time spent in immobility each mi-
nute of the 5-min test. 
In the graph below (Fig. 3.4), time spent climbing by each group of rats is shown: 
only female rats seem to show differences in the performance, with CLI females spend-
ing the lowest amount of time in climbing activity compared to Sal females and also to 
males. Even if a certain variability within the groups of animals is evident, a significant 
treatment effect (F (1,37) =4.456, p<0.05), with CLI rats spending a lower amount of  time 
climbing than Sal rats, and a trend towards a sex*treatment interaction effect (F (1,37) 
=2.94, p=0.096) were found with a Two-way ANOVA. 
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Fig. 3.4 - Climbing activity during FST in young animals. 
3.3.2.1.2 Treatment and age correlation  
FST performance was compared among all the age groups of animals, and is de-
scribed in the following two charts, showing time spent in immobility (Fig. 3.5A) and 
climbing (Fig. 3.5B) by CLI and Sal rats. While young and middle-aged rats showed a 
similar attitude in immobility rate, aged rats significantly spent more time in immobility 
compared to the other two age groups (Two-way ANOVA, F (2,32) = 3.594, p<0.05). As 
shown in Fig. 3.4 and described in section 3.3.2.1.1, CLI young rats showed a significant 
effect of treatment in climbing activity but the same cannot be said for the middle-aged 
and aged groups, as confirmed by the trend towards  a treatment*age interaction (F (2,32) 
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= 3.040,  p=0.64) effect found with Two-way ANOVA. Furthermore, only a trend towards 
an age effect was found (F (2,32) = 2.667, p=0.88). 
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Fig. 3.5 - Comparison of a) immobility and b) climbing activity in the FST among the three age groups. 
3.3.2.2 Sucrose preference test 
3.3.2.2.1 Treatment and sex correlation in young animals 
The chart below (Fig. 3.6) shows the total liquid intake over the 48-hr training 
phase, separately for water and sucrose consumption: all the animals preferred sucrose, 
with no differences in water intake. In particular, CLI male rats showed a significantly 
higher sucrose consumption compared to Sal male rats (p<0.05). Female animals did not 
show the same preference, as demonstrated by the significant main effect of sex (F (1,37) 
=3.92, p<0.05) and by the sex*treatment interaction effect (F (1,37) =10.622, p<0.01) on 
sucrose consumption.  
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Fig. 3.6 - Total water and sucrose solution intake, after the 48h habituation phase of the SPT of the 
young group of animals.  
The chart below reports the percentage of sucrose consumption, over the total 
liquid intake, measured during the 2h-test phase (Fig. 3.7). The higher sucrose consump-
tion of CLI male rats compared to Sal male rats was evident, whereas females showed no 
48 Cristina Tognoli 
differences due to treatment. As in the habituation phase, a significant effect of sex 
(Two-way ANOVA, F(1,37) =4.89, p<0.05) and a sex*treatment interaction (Two-way 
ANOVA, F (1,37) =9.05, p<0.01) were found, suggesting that the hedonic behavior of ani-
mals did not consistently change after the 18h stressful event of food and water depriva-
tion. 
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Fig. 3.7 - Sucrose preference score in the young group of animals in the 2h-test. 
3.3.2.2.2 Treatment and age correlations 
Graph reported in Fig. 3.8 shows the sucrose consumption over the total liquid 
intake in the three age groups during the 2h test: a treatment effect seems to be present 
in the middle-aged group, with CLI rats exhibiting a lower consumption of sucrose com-
pared to Sal rats. Furthermore, aged rats, without any distinction between CLI and Sal 
animals, consumed less sucrose than the other two age groups. Multivariate ANOVA 
showed a significant age effect (F(2,32) = 9,795, p=0.001), but no treatment or treatment 
*age interaction effects in the 2h-test. Further analysis showed a significant effect of age 
in sucrose preference scores measured in both the first and the second day of habitua-
tion (data not reported) and a trend towards a treatment effect (F (1,32) =3.839, p=0.06) 
in the second day of the habituation phase (not shown). The Post-hoc analyses 
(Bonferroni) showed a significant difference between the aged and the young group in 
all the three phases of the behavioral test, and a significant difference between the aged 
and the middle-aged group in the habituation phase, but not in the 2h test. 
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Fig. 3.8 - Sucrose preference score after the 2h test in the three age group. 
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3.3.3 Brain MRI volumetry 
3.3.3.1 Young animals 
The graphs in Fig. 3.9 show the volumes of a) total brain and b) hippocampus 
measured in the young group of animals measured in mm3.  
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Fig. 3.9 - Volumetric analysis of a) total brain and b) hippocampus of young animals. 
A Two-way ANOVA demonstrated a treatment effect in total brain volume (F (1,25) 
=11.84, p<0.05) with CLI rats showing a smaller brain compared to Sal rats. Also hippo-
campal volumetric analysis, performed without any manipulation/normalization of data, 
confirmed the presence of a treatment effect: in CLI rats we observed a smaller hippo-
campus compared to Sal rats (F (1,25) = 5.23, p<0.05). Interestingly, we found a significant 
effect of treatment on volume of lateral ventricles: CLI rats (Fig. 3.10A) exhibited en-
larged ventricles compared to Sal rats (Fig. 3.10B) (F (1,25) =5.28, p<0.05). Treatment did 
not affect the volume of prefrontal cortex and did not affect in a different way the vol-
ume of brain regions of males and females. 
We made a further investigation of the hippocampal reduction and of the ventric-
ular enlargement observed by performing Univariate ANOVA for each of the two regions 
with total brain volume as covariate. Hippocampal volume of CLI animals showed no 
more significant reduction compared to Sal animals, while total ventricles were con-
firmed to be significantly enlarged in CLI animals compared to Sal animals (F (1,25) = 
4.624, p<0.05). This important observation has been already reported in depressed 
(Kempton et al., 2011) and schizophrenic patients (Kempton et al., 2010; Meduri et al., 
2010). 
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Fig. 3.10 - MRI total ventricular volumetry in the young group of animals: A, CLI rats; B, SAL rats. 
3.3.3.2 Age comparisons 
In a comparison of total brain volumes between young and aged animals, no age 
effects were found. Further, aged brains did not show any differences due to a treatment 
effect (not shown). 
The graphs reported in Fig. 3.11 show the comparison made between young and 
aged rats of a) prefrontal cortex (PFC) and b) hippocampal volumes. For what concern 
PFC, the chart shows slight differences between CLI and Sal animals, and a little reduc-
tion in volume for aged rats compared to young. Results from a Two-way ANOVA 
showed trends towards age (Two-way ANOVA, F (1,21) =3.170, p=0.09) and treatment 
(Two-way ANOVA, F (1,21) =3.948, p=0.06) effects. 
For what concerns the analysis of hippocampal volumes (Fig. 3.11B), aged rats 
showed a bigger hippocampus compared to young animals, but not relevant differences 
due to treatment.  A significant effect of age (Two-way ANOVA, F (1,21) =6.813, p<0.05) 
was found without any manipulation of data, and this result was confirmed also in a 
Univariate ANOVA with total brain volume as covariate factor (F (1,21) =13.751, p<0.01).  
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Fig. 3.11 - MRI volumetric analysis of a) prefrontal cortex, and b) hippocampus in aged and young 
rats. 
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3.3.4 BDNF analysis 
The chart in Fig. 3.12 shows the quantity of BDNF, expressed as quantity of BDNF 
(ng) over the total amount of protein (µg), measured in hippocampus and total cortex. A 
significant decrease in BDNF levels was found in hippocampus of CLI rats (One-way 
ANOVA, F (1,8) = 14.394, p<0.01) but no difference were found in cortical levels. 
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Fig. 3.12 - Levels of BDNF in hippocampus of Sal and CLI rats. 
 
3.3.5 Cell counting 
3.3.5.1 Young animals 
The graphs below report the total number of DCX+ (Fig. 3.13A) and BrdU+ (Fig. 
3.13B) cells. Females showed a lower number of both DCX+ and BrdU+ cells. A treat-
ment effect can be noticed only in BrdU+ cell counts, with CLI animals showing a lower 
number of cells compared to Sal animals in both males and females. A Multivariate 
ANOVA showed a significant sex effect in both total DCX+ cell counts (F (1,22) =21.208, 
p<0.001) and BrdU+ cell counts (F (1,22) =4.384, p=0.05) and a treatment effect was ob-
served in BrdU+ cell counts (F (1,22) =5.289, p<0.05).  
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Fig. 3.13 - Effects of sex and treatment on total counts of a) DCX+ and b) BrdU+ cells. 
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3.3.5.2 Age comparisons 
As shown in the graph below (Fig. 3.14A), the number of DCX+ cells was signifi-
cantly lower in aged animals than in young animals. A two-way ANOVA showed an age 
effect (F (1,19) =221.604, p<0.001). Age effect was significant also for BrdU+ (F (1,19) 
=10.158, p<0.01) and for double-labeled (Fig. 3.14B) cell counts (F (1,19) =16.787, 
p=0.001). Representative microphotographs from BrdU/DCX immunohistochemistry in 
young and aged animals are shown in Fig. 3.15.  
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Fig. 3.14 - Age effect on a) DCX+ and b) double-labeled cells of the subgranular zone of the hippo-
campus.
 
Fig. 3.15 - Representative microphotographs of DCX+ cells in young and aged animals. 
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3.3.6 Cell morphology 
The statistical analysis of the parameters measured was performed as described 
by Rao (Rao et al., 2005): the value of every parameter was first calculated separately 
for each animal and then means and standard deviations  were determined for the total 
number of animals included per group.   
DCX+ cells were analyzed for the total length of apical dendrites, total number of 
nodes and for the pattern of dendritic growth and of node distribution away from the 
soma. No differences in total number and pattern of distribution of dendritic nodes were 
found; branching pattern of the dendritic growth away from the soma revealed a sex dif-
ference in the first 10 µm of distance from soma, with granule cells of females showing a 
significantly higher branching than those of males (Multivariate ANOVA,  F (1,22) =11.887, 
p<0.01)(Fig. 3.16, marked by red circle). Furthermore, a trend towards a treatment ef-
fect (Multivariate ANOVA, F (1,22) =2.748, p=0.093) was found  at 30 µm of distance from 
soma, with CLI rats exhibiting a higher branching than Sal rats) (Fig. 3.16, marked by 
green circle). Dendritic arborization over a distance of 150 µm was significantly reduced 
or even not present in some of the cells analyzed. 
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Fig. 3.16 - Morphological Sholl profile of young animals: effect of sex (red circle) and a trend towards 
a treatment effect  (green circle) on the dendritic arborization pattern of DCX+ granule cells analyzed 
in the subgranular zone of the hippocampal dentate gyrus. 
Chart reported in Fig. 3.17 shows a significant treatment*sex interaction effect in 
total dendrite length: CLI males showed a major total dendrite length compared to Sal 
males, while in females the trend is opposite (Multivariate ANOVA, F (1,22)=5.07, p<0.05). 
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Fig. 3.17 - Total dendrite length measured in DCX+ granule cells of young animals. 
A further morphological analysis was performed on the soma, evaluating charac-
teristics such as perimeter, area (referred to XY projection of the 2D images reconstruct-
ed at the plane of the sharpest focus, i.e. the focus calculated at the midpoint of the Z-
plane extreme focuses), feret maximum, that is the longest diameter of the soma, and 
feret minimum, the longest diameter perpendicular to the feret maximum. Females 
showed decreased values in all the components examined, as shown in the four graphs 
reported in Fig. 3.18. Furthermore, only females seemed to exhibit a certain degree of 
treatment effect, with CLI animals showing decreased perimeter, area, and Feret maxi-
mum and minimum. Statistical analysis (Multivariate ANOVA), whose results are entire-
ly reported in Table 3.3, showed a sex effect in all parameters measured. A 
sex*treatment interaction effect and a trend towards a treatment interaction effect were 
found only in the measure of Feret maximum, with CLI females showing a decreased 
Feret maximum compared to Sal females, while no effect was observed in males. A trend 
towards a sex*treatment effect was found also in the measure of perimeter, again with 
the same observations made for Feret maximum. 
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Fig. 3.18 – Somatic neuron components analyzed in selected DCX+ cells of young females and males 
with the Branched structure analysis: a) perimeter, b) area, c) Feret max, and d) Feret mimum. 
Somatic pa-
rameter 
Sex Treatment Sex*treatment 
F p value F p value F p value 
Perimeter 19.567 <0.001* 2.121 0.162 3.408 0.081 
Area 11.551 0.003* 2.162 0.159 1.914 0.183 
Feret maxi-
mum 
15.448 <0.001* 3.580 0.075 5.293 0.034* 
Feret mini-
mum 
11.766 0.003* 1.301 0.269 0.104 0.751 
Table 3.3 – Multivariate ANOVA results of the analysis of morphological somatic parameters of DCX+ 
cells in young animals. Animals: 13 males, 9 females; 12 Sal, 10 CLI. (*)= statistical significant results 
for α value =0.05. 
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3.3.6.1 Glial fibrillary acidic protein (GFAP) immunohistochemistry and densitometric 
analysis of astrocytic immunosignal  
3.3.6.1.1 Young animals 
All areas in which GFAP i-r was measured showed a significant sex difference 
with female rats exhibiting a higher astrocytic density compared to male rats. In Fig. 
3.19, graphs relative to GFAP i-r measured in a) sensitive cortex and b) hippocampal 
hilus show that CLI females have a lower astrocytic density compared to Sal females, 
while in males no treatment effect is evident. Table 3.4 reports the results of the Multi-
variate ANOVA performed. As expected, in the region of motor cortex, no treatment ef-
fect was found. Furthermore, all brain regions, with the exception for motor cortex, 
showed a significant sex*treatment interaction effect, with CLI females showing a lower 
astrocytic density compared to Sal females, but no differences in males.  
 
Brain region Sex Treatment Sex*treatment 
F p value F p value F p value 
Cingulate 
cortex 
156.691 <0.001* 1.812 0.194 8.667 0.008* 
Motor cor-
tex 
51.437 <0.001* 0.490 0.493 3.354 0.083 
Parietal cor-
tex 
32.832 <0.001* 4.660 0.044* 6.391 0.020* 
Hippocampal 
hilus 
70.576 <0.001* 5.446 0.031* 15.885 0.001* 
Hippocampal 
CA2 
58.232 <0.001* 1.662 0.213 7.019 0.016* 
Table 3.4 - Statistical results of Multivariate ANOVA of GFAP i-r in different brain regions. N=23, 11 
CLI rats and 12 Sal rats; 14 males and 9 females. 
The clomipramine model of depression in the rat  57 
G
FA
P 
i-r
 
(O
D
)
0.0
0.1
0.2
0.3
0.4
0.5
Sal
CLI
males females
G
FA
P 
i-r
 
(O
D
)
0.0
0.1
0.2
0.3
0.4
0.5
Sal
CLI
males females
a) b)
 
Fig. 3.19 - GFAP i-r expressed as optical density (OD) in the sensitive cortex (a) and hippocampal hilus 
(b) of young male and female rats. In these two regions there was evidence of sex, treatment and 
sex*treatment interaction effects. 
3.3.6.1.2 Age comparisons 
In Fig. 3.20, scatter plots relative to GFAP i-r in a) cingulate cortex and b) hippo-
campal CA2 show a different pattern of the effect of clomipramine treatment: CLI aged 
animals exhibited an augmented GFAP i-r compared to Sal aged rats, while in young an-
imals the trend is opposite. In Table 3.5 all results from the Multivariate ANOVA per-
formed are reported. In the comparison between young and aged female rats, a trend to 
an age effect was found only in motor cortex, with young rats showing a higher GFAP i-r 
than aged rats . No treatment effects were evident in any region. Effects of age* treat-
ment interaction were found in all regions analyzed. In Fig. 3.21 representative micro-
photographs of the GFAP immunohistochemistry in both young and aged animals are 
shown. 
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Fig. 3.20 - Age comparison  in GFAP i-r in cingulate cortex (a) and hippocampal CA2 (b) of female rats. 
Neonatal clomipramine treatment shows an inversion of effect in GFAP i-r in the elderly compared to 
early age. 
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Brain region Age Treatment Age*treatment 
F p value F p value F p value 
Cingulate cor-
tex 
2.639 0.124 0.406 0.533 10.143 0.006* 
Motor cortex 4.238 0.056 0.258 0.619 7.347 0.015* 
Sensitive cor-
tex 
0.005 0.943 0.000 0.983 11.840 0.003* 
Hippocampal 
hilus 
0.064 0.804 0.1692 0.212 7.237 0.016* 
Hippocampal 
CA2 
0.266 0.613 0.015 0.904 10.776 0.005* 
Table 3.5 - Statistical results of Multivariate Anova of GFAP i-r in different brain regions. N=20, 10 CLI 
rats and 10 Sal rats; 9 young and 11 aged. 
 
Fig. 3.21 – Representative microphotographs from GFAP immunohistochemistry in the hippocampus 
of young and aged animals. 
3.4 Conclusions 
The results obtained so far raise several considerations on the effects of neonatal 
clomipramine treatment in males and females and their persistence during adulthood 
and aging. 
• In young animals, the most straightforward indication obtained is the decrease in 
total brain volume and an enlargement of total ventricular volume of CLI com-
pared to Sal rats, as demonstrated by the MRI studies. These results are in line 
with clinical (Sheline, 2000; Kempton et al., 2011) and preclinical studies on oth-
er animal models of depression who showed a reduction  of brain volume and an 
enlargement of lateral ventricles (Wrynn et al., 2000). 
• BDNF decrease in CLI animals may be the responsible of the qualitative observa-
tions on morphological dystrophic features of neurons observed in previous ex-
periment (section 2.3.4). 
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• Behavioral testing yielded different effects in females vs. males, suggesting a sex-
dependent susceptibility to the treatment or possibly a different recovery time. 
The data reported described for the first time a gender-dependent effect in the 
neonatal clomipramine model of depression, in line with many studies that re-
peatedly reported sex differences in animal models of depression and antide-
pressant response (Dalla C. et al., 2009); sex differences during aging remain to 
be investigated. 
• In aged animals, behavioral, neurogenic, and brain structural changes typical of 
aging, with a flattening of the effects of treatment suggest a degree of long-term 
recovery from the picture seen in young rats; 
• The group of middle-aged animals may represent an intermediate phase between 
the early treatment effects and the subsequent recovery. 
These findings confirmed in part data reported by Vogel (Vogel et al., 1990a): the 
effects of neonatal clomipramine treatmentare likely to appear in the adulthood and to 
persist for a certain period of time. To the best of our knowledge, the effects on animals 
before the three months of age have not yet been described. 
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4 Study 3 – Effects of acute stress in clomipramine treated 
rats 
4.1 Introduction  
The last experiment was aimed at the investigation, in the neonatal clomipramine 
model, of the possibility that a stress event, in the adult age, might exacerbate behavioral 
depressive symptoms and influence some neurobiological substrates. It has been re-
peatedly reported that patients suffering from depression show an increased reactivity 
to stress and contemporarily show a dysregulation of the HPA axis (Holsboer, 2000; 
Holsboer and Ising, 2010). Life experiences characterized by a stressful component elicit 
a complex variety of behavioral and physiological changes believed to contribute to ideal 
coping of the organism with the situation including the activation of HPA axis (Girotti et 
al., 2006). Considering that in human life stressful events are daily and, as said above,  
can trigger a latent depressive syndrome, also through the chronic elevation of 
glucorticoid levels due to HPA axis activation (Girotti et al., 2006), it is necessary to con-
sider that maybe it is paid too much attention in protecting lab animals thus creating a 
not-realistic environment. The behavior of CLI animals could be masked by the protect-
ed environment in which they live. Could a controlled acute stress in the adulthood in-
duce the coming out of behavioral depressive symptoms of early-life treated animals?  
The study was divided into two phases: 
4.  behavioral and neurobiological characterization of neonatal clomipramine expo-
sure in the animals; 
5. investigation of behavioral and neurobiological correlates of the interaction be-
tween pharmacological treatment in early life and an acute stress event in the 
adult age. 
Restraint stress is the type of stress chosen for our aims: it is a kind of mild 
stressoror, often used in protocols of chronic mild stress induced depression in rodents 
(Bessa et al., 2009; Reich et al., 2009), and it is considered to be primarily a psychologi-
cal stress because it does not produce pain or direct physical insult (Girotti et al., 2006). 
Among the procedures for behavioral assessment, here the elevated plus maze 
(EPM) test was adopted to study anxiety trait in our animals in basal conditions and af-
ter a stressful event. The maze is a cross-shaped apparatus elevated from the floor, with 
2 open arms, two enclosed arms with high walls, and an open central zone. Rodents are 
put in the central zone with the head in the direction of one open arm and left free to 
move on the apparatus for 5 minutes. No training is performed, so the behavior of ani-
mals is spontaneous and unconditioned. The test is a paradigm on the relationship be-
tween novelty, fear of the open spaces and exploration (Rodgers and Dalvi, 1997).  The 
measure of time spent and of number of entries in both open and closed arms are em-
ployed as measures of locomotor and exploratory activity. The more animals spend time 
in closed arms, the more they show an anxious behavior. 
Another method to study exploratory behavior, locomotor activity and anxiety 
trait is the open field test, that herein is represented by a larger cage (for the descrip-
tion, see paragraph 4.2.3.2) enriched by several objects. Animals in a novel enriched en-
vironment show reduced aggression, anxiety, fear, stress and an increase in learning 
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abilities (Ilin and Richter-Levin, 2009) and are induced to react to novelty and to explore 
it.  
 
In order to complete a series of neurochemical analyses performed in the previ-
ous experiments, the serotonin transporter (SERT) distribution was analyzed with the 
immunohistological technique in several brain regions of our animals. SERT  is a mem-
brane protein that transports the neurotransmitter serotonin from synaptic spaces to 
presynaptic membrane, in order to block serotonin’s action and recycle it. Because of its 
function, SERT has become in the last years one of the favorite targets of the most used 
antidepressant agents, the SSRIs.  
SERT was found also in cells outside the central nervous system, including blood 
platelets, lymphocytes, and enterochromaffin cells of the intestinal epithelium. A de-
crease in peripheral blood platelet SERT binding is a biomarker of depression (Rivera-
Baltanas et al., 2012). Further observations about a decrease in lymphocyte SERT ex-
pression in depressive patients were reported and it may be related to an increase in in-
flammatory cytokines with a role in the pathophysiology of depression (Rivera-Baltanas 
et al., 2012). SERT is relevant to the neuroanatomy of depression, given its localization 
in cortical, striatal, and limbic areas (Smith et al., 2011). In vivo imaging and post-mortem 
studies showed a lower SERT binding in brain regions, such as prefrontal cortex, of de-
pressed patients, maybe due to a decrease in SERT gene expression (Arango et al., 
2001). In animals neonatally exposed to citalopram, SERT  expression was found re-
duced in the medial prefrontal cortex, primary somatosensory cortex (Maciag et al., 
2006) and throughout the entire hippocampus (Weaver et al., 2010), and these effects 
persisted in adulthood. 
4.2 Material and methods 
4.2.1 Animals 
Pregnant Sprague-Dawley rats (Harlan), were put on a 12:12h light/dark cycle 
(lights on at 8:00 am) and maintained at room temperature (20±2°C) with food and wa-
ter ad libitum.  
4.2.2 Treatment groups 
At birth, animals were divided into three treatment groups: CLI, Sal, and untreat-
ed (Untr) rats. CLI and Sal animals were subcutaneously injected twice daily, from post-
natal day (PND) 5 to 21, with 20 mg/kg clomipramine and saline solution, respectively. 
Injections were administered outside of the animals' home cage, which implied repeat-
ed, albeit short, maternal separations. Untr rats were left undisturbed for the entire pe-
riod, until weaning. After weaning, animals were housed individually in standard rat 
cages and adapted to the laboratory's inverted 12:12h light/dark cycle (lights-on at 7 
pm). The choice to adopt the inverted light/dark cycle was considered important to test 
animals in their natural wake phase, the dark phase, and measuring a spontaneous per-
formance. Diversely, in both Experiment 1 and 2 animals were tested during the light 
phase.  
In Fig. 4.1 a diagram of the experimental  procedures to which animals were sub-
jected is reported. Each experimental assessment was staggered from the previous of at 
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least one week to allow animals to recover. These pauses were also necessary to avoid 
any interference in the outcome of experimental testing due to the stress that proce-
dures themselves induce in animals. 
 
Fig. 4.1 - Diagram summarizing the experimental activities and animal groups involved in Experiment 
3. 
4.2.3 Pre-stress testing  
4.2.3.1 Elevated Plus Maze Test 
At PND60, all rats were subjected to the Elevated Plus Maze (EPM) test. Each rat 
performed a 5-min test, without any training session. Their performance on the instru-
ment, which has been already described in section 4.1, was videotaped by a camera posi-
tioned at the centre of the ceiling of the testing room and then, with the help of the 
Ethovision software (Noldus®), which detected and recorded the positions of animals on 
the instrument with the frequency of 25 frames per second, parameters like distance 
moved, velocity, and time spent in specific zones were calculated. 
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4.2.3.2 Novel enriched environment 
Immediately after the 5-min EPM session, animals were transferred to a novel, en-
vironment represented by Phenotyper cages, that were enriched with pieces of paper, 
bottle tops, and other stimulating objects for animals. Phenotyper cages are cages with 
plexiglas walls provided of holes for the airing of the cage, with interchangeable black or 
white bottoms, according to the fur color of the animals, and with a videocamera posi-
tioned at the top of the cage supplied with adjustable infrared lights. The Ethovision 
software (Noldus®) can analyze video-recordings with the frequency of 25 frames per 
second, thus allowing the experimenters to know with a high precision animals’ move-
ments inside the cage. Animals stayed inside the cage for 24h and 24h-videotapes are 
still in a preliminary stage of elaboration and analysis and in the present thesis they will 
not be presented. 
4.2.4 Acute stress 
One week after the above described assessement, half of each group of animals 
underwent an acute stressful event (stressed), while the other half stayed undisturbed 
in their cages (controls). Specifically, each stressed animal was put in a wire mesh re-
strainer for 4h and left undisturbed in its home cage. The condition did not allow the an-
imals, to move, to feed and drink water. 
4.2.5 Post-stress testing 
Immediately following the acute stress, all the animals were re-tested for anxiety 
trait in the EPM test and for locomotor activity in the Phenotyper cages as described in 
sections 4.2.3.1 and 4.2.3.2, respectively.  
After 1 week, animals were tested for depression with SPT and then with FST. 
4.2.5.1 Sucrose Preference Test  
The procedure adopted for SPT was the same described in section 3.2.4.2 
4.2.5.2 Forced Swim Test 
The procedure adopted for FST was the same described in section 3.2.4.1. 
4.2.6 Perfusion and brain processing 
At ~PND90 rats were deeply anesthetized, transcardially perfused with a NaCl 
0.9% solution followed by a tissue fixation with cold paraformaldehyde (4% in PBS), and 
their brains were removed and stored in 30% sucrose at 4°C until they sank. Brains 
were then frozen at the microtome and cut in 40 µm coronal sections, which were pre-
served in 0.1M PBS with 0.1% NaN3 until histological processes.  
4.2.7 DCX immunohistochemistry 
The procedure adopted was the same described in section 2.2.7, with the excep-
tion that counts were performed by visual inspection in the entire dentate gyrus of three 
evenly spaced section spanning the whole hippocampus. 
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4.2.8 SERT immunoistochemistry:  
After incubation in 3% H2O2 and 10% MetOH in 0.1M PBS for 10 min for peroxi-
dase inactivation, sections were blocked in 5% NHS + 0.3% Triton X-100 in PBS for 1h. 
Then sections were incubated overnight with a monoclonal mouse anti-SERT 
(Chemicon; 1:1000) diluted in PBS containing 3% NHS+ 0.3% Triton X-100 overnight at 
room temperature; incubation in secondary antibody (biotinylated horse anti-mouse 
IgGs; 1:200, Vector) diluted in PBS containing 3% NHS + 0.3% Triton X-100 was per-
formed for 1h at room temperature. Then the staining was developed with the ABC kit 
(incubation for 1h at RT) followed by an incubation in 0.1M PBS containing 0.05% NiCl + 
0.025% DAB + 0.003% H2O2 for 5 min. All the washes were done with 0.01M PBS con-
taining 0.1% of Triton X-100. 
4.2.8.1 SERT densitometry  
Photographs at high magnification were taken with a digital camera connected to 
a microscope (objective 40X ) and background signal (non specific SERT i-r signal) was 
calculated for each frame chosen from the areas of interest in the selected coronal sec-
tions (Table 4.1) (relative to Bregma according to Paxinos and Watson, 1998). SERT i-r 
values were normalized to OD values with the following formula:  
1-(ODx/ODb) 
where ODx is the OD of the brain area considered, and ODb is the OD of the back-
ground measured in the same section of the brain area analyzed. 
Brain area frames per side per animal Bregma 
Cingulate cortex 4 0.00 
Entorhinal cortex 2 -5.40 
Hippocampal CA2 4 -3.48 
Hippocampal hilus 4 -3.48 
Table 4.1 - Number of frames selected from the brain areas of interest. Bregma levels are relative to 
those reported by Watson and Paxinos, 1998. 
4.3 Results 
4.3.1 Body weight 
Body weight was monitored daily throughout the period of treatment in CLI and 
Sal treated rats: as shown in chart in Fig. 4.2 and as reported in previous experiments, 
CLI animals showed a significant decrease in body growth rate compared to Sal animals 
(Repeated measures ANOVA with F (1,50) = 93.621, p<0.001). No weight monitoring was 
performed in Untr animals to avoid maternal separation. 
The clomipramine model of depression in the rat  65 
Post-natal Day
Bo
dy
 
w
e
ig
ht
 
(g)
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
0
20
40
60
Sal
CLI
 
Fig. 4.2 - Body growth rate of CLI and Sal animals during the 17-day period of treatment. Untr animals 
were not weighed to avoid any stress and maternal separation. 
4.3.2 EPM test 
We evaluated the amount of locomotor activity in the EPM by measuring the total 
distance moved by the animal during the 5-minute test. In the session that preceded the 
restraint stress, no significant differences among the treatment groups were observed.  
After this first observation, we analyzed data as comparison between the two perfor-
mances (preceding and following restraint) of each rat in the EPM test: to make this pos-
sible, data were elaborated as normalized index of the after- versus before-stress 
locomotor activity. The chart in Fig. 4.3 shows the differences in the performances of 
control and stressed animals: control animals did not show any significant difference in 
the performance of EPM test, while stressed animals showed a decrease in locomotor ac-
tivity in the second session compared to the first (Univariate ANOVA, F (1,61) = 3.943, 
p=0.05). A treatment effect was observed (F (2,61) = 4.648, p=0.014) and post-hoc anal-
ysis showed that CLI animals moved significantly less than Untr animals (p=0.018). 
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Fig. 4.3 - EPM test: normalized index of locomotor activity of after- (A) versus before- (B) stress per-
formance ((A-B)/(A+B)). 
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In Fig. 4.4, representation of the negative effect of stress on the performance of 
EPM test is reported: distance moved by b) stressed animals was significantly dimin-
ished in the 2nd assessment, while no differences were detected in the performances of 
a) control animals.  
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Fig. 4.4 - Performance in the two sessions of EPM test in a) control animals and b) stressed animals. 
Charts reported in Fig. 4.5 show time spent in closed arms of EPM in the a) first 
session and b) second session. Animals seem not to be influenced by treatment in basal 
conditions as shown in graph a), and the repetition of the same test after one week did 
not induce any difference in the performance of controls. Furthermore, the repetition of 
the EPM test after a stressful event does not seem to affect the exploratory activity. 
Further analyses are ongoing to refine the measurement of exploratory versus “anxious” 
behavior as function of animal’s distance from maze centre. 
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4.3.3 Assessment of depressive symptoms 
4.3.3.1 Sucrose Preference Test 
The chart in Fig. 4.6 shows the percent of sucrose consumption over the total liq-
uid intake during the 2h test. Even if, in a certain degree, CLI animals of both control and 
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stressed groups showed a decrease in sucrose consumption, Univariate ANOVA did not 
show either treatment or stress effect. 
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Fig. 4.6 - Sucrose preference score in experimental groups; sucrose score was calculated as sucrose 
consumption over the total liquid intake. 
4.3.3.2 Forced Swim Test 
In Fig. 4.7, graph a) reports the amount of time spent in immobility and graph b) 
the amount of time spent in climbing during the FST. From the control group, Untr ani-
mals showed an expected decrease in time spent in immobility, but statistical analysis 
showed no differences due to treatment. In the analysis of stress effect, no differences 
were found among groups in the amount of time spent in immobility. For what concern 
climbing activity, CLI animals spent less time than the other treatment groups in climb-
ing activity and, in general, stress seem to basically affect the performance of Untr ani-
mals. Multivariate ANOVA showed treatment (F (2,50) = 14.868, p<0.001) and stress (F 
(1,50) = 9.971, p=0.003) effects. Furthermore a treatment*stress interaction (F (2,50) = 
3.117, p=0.05) effect was shown. Post-hoc analyses of climbing activity showed that the 
three treatment groups significantly differ from each other. 
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Fig. 4.7 - Time spent in a) immobility and b) climbing during the FST by the experimental groups of 
animals: time was expressed as percent of total test duration. 
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4.3.4 Neurogenesis study 
Sacrifice of animals was executed in a period quite far from the one in which re-
straint stress was administered to animals, anywhere the investigation on a possible ef-
fect on neuronal proliferation was performed. The chart in Fig. 4.8 show DCX+ cell 
counts performed in 3 sections evenly spaced spanning the entire dentate gyrus of hip-
pocampus of each animal. The chart shows that Untr animals exhibited the lowest num-
ber of DCX+ cells of all the treatment groups, and that stress seemed to affect treated an-
imals but not Untr group. Multivariate ANOVA showed a significant effect of treatment 
on the number of DCX+ cells (F (2,23) = 6.127, p<0.01), and post-hoc analysis (Bonferroni) 
showed that Untr animals had a significant lower number of cells compared to both Sal 
(p=0.009) and CLI (p=0.05) animals. Stress significantly decreased the number of cells in 
animals (F (2,23) = 23.716, p<0.001) 
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Fig. 4.8 - Number of DCX+ cells in the hippocampal subgranular zone of the experimental groups of 
animals. 
4.3.5 SERT densitometry 
In Fig. 4.9, representative microphotographs from SERT immunohistochemistry 
show qualitative distribution of the protein within the cingulate cortex, hippocampal 
CA2 and hilus, and the entorhinal cortex. 
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Fig. 4.9 - Representative microphotographs of SERT-labeled fibers from the different areas of each 
treatment group of animals are reported.  
Graphs in Fig. 4.10 show quantitative SERT analysis in a) hippocampal hilus and 
b) cingulate cortex performed with densitometry. CLI animals show a reduction in SERT 
i-r in the region of hippocampal hilus and in the cingulate cortex the reduction in CLI an-
imals seem to be potentiated by stress. Statistical results from Multivariate ANOVA re-
ported in Table 4.2 revealed a significant treatment effect in  both the hippocampal are-
as analyzed, hilus and CA2, and in cingulate cortex. As expected, no treatment effects 
were found in entorhinal cortex. Neither effect of stress nor stress*treatment interaction 
was found. 
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Fig. 4.10 - SERT i-r in hippocampal hilus and cingulate cortex of all animal groups. Post-hoc analysis of 
treatment effect (Bonferroni) showed significant differences in SERT i-r in hippocampal hilus between 
CLI and Sal animals (p=0.006) and in the cingulate cortex between Sal and Untr animals (p=0.035). 
 
Brain region Treatment Stress Stress*treatment 
F p value F p value F p value 
Cingulate cor-
tex 
3.850 0.037* 0.009 0.925 1.364 0.277 
Hippocampal 
CA2 
8.018 0.002* 0.509 0.483 1.257 0.483 
Hippocampal 
hilus 
6.186 0.007* 0.167 0.687 0.339 0.716 
Entorhinal 
cortex 
1.302 0.292 0.002 0.961 0.820 0.453 
Table 4.2 - Statistical results of Multivariate Anova of SERT i-r in different brain regions. N=28, 10 CLI, 
10 Sal, and 8 Untr rats; 14 controls and 14 stressed animals. 
4.4 Conclusions 
Results from EPM test suggest an interaction between early life treatment and 
stress in adulthood. As in previous experiments, SPT did not show any significant effect 
of treatment and stress seemed not to influence anhedonic behavior, but results from 
FST confirmed the presence of despair behavior in CLI animals, with stress as an influ-
encing factor. 
Neurogenesis study confirmed preliminary results, showing no differences between CLI 
and Sal animals in the number of DCX-labeled cells; curiously, both CLI and Sal animals 
showed a higher number of cells compared to Untr animals, maybe for a compensatory 
effect from the early-life insult. The decrease of cell number in hippocampus after a 
stressful event has been already described in literature (Paizanis et al., 2007). 
SERT expression was found to be affected by treatment in a region-dependent way: re-
sults obtained can be paralleled with those found by Weaver and colleagues ((Weaver et 
al., 2010), who found a reduction in SERT expression in the hippocampus of rats 
neonatally treated with citalopram, suggesting the profound impairment in the neuro-
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transmitter circuitry due to neonatal treatment with antidepressants. The absence of a 
stress effect I controversial if compared to the observations made in the neurogenesis 
study: it is still matter of discussion the effect that a stressful event can still exert in an 
epoch far from the sacrifice time on biological substrates such as cell proliferation and 
neurotransmitters’ circuitry.  
Ongoing analyses of locomotor activity in a novel enriched environment and 
Parvalbumin circuitry in specific brain areas are fundamental to complete the picture of 
the possible interaction between stress and treatment.  
 
72 Cristina Tognoli 
5 Discussion 
The results of the investigations carried out and herein reported show that neo-
natal exposure to the tricyclic antidepressant clomipramine induce in adult rats a com-
plex picture of behavioral and neurobiological abnormalities that could be correlated to 
a depressive syndrome or, in a simplistic way, to a ‘neonatal antidepressant exposure 
syndrome’, using the definition of Maciag (Maciag et al., 2006) to indicate the “pattern of 
maladaptive behaviors that are evident long after drug discontinuation and persist into 
adulthood” (cited from (Maciag et al., 2006).  
Exposure to antidepressants has been reported to induce effects of different per-
sistence and entity according to age of administration: adults exposed to antidepressant 
therapy exhibited no more behavioral effects after drug discontinuation; on the contra-
ry, if women were cured during pregnancy and lactation with antidepressants for the 
treatment of affective disorders, their children showed signs of antidepressant with-
drawal in the first weeks of life and some of them displayed behavioral abnormalities in 
motor development and control in their first few years of age (Casper et al., 2003; Sanz 
et al., 2005), influenced also by the gestational period and duration of treatment (Casper 
et al., 2011). 
We did not perform a study on the effects of antidepressant treatment in rats 
during the period of administration or in the first days after drug discontinuation, but a 
longitudinal study at different ages from adulthood, through middle-age, until old age, 
was carried out, in order to assess the persistence of behavioral and neurobiological im-
pairments. Vogel reported about a gradual, and maybe independent of live events, de-
velopment of the set of behavioral abnormalities, with a peak at age 6-7 months fol-
lowed by a spontaneous remission of the symptoms after several months (from age 10-
11 months) from drug discontinuation, even if it was observed only in a subset of behav-
ioral contexts such as REM sleep study and open field tests (Vogel et al., 1990a; Vogel et 
al., 1990b). Here we showed  that neonatal clomipramine treatment significantly affect-
ed locomotor activity in the FST and self-reward behavior in the SPT in young animals 
(age 3-5 months), but CLI aged animals did not show any differences when compared to 
Sal aged animals (age 17-19 months). Furthermore, we conducted our behavioral anal-
yses in an additional age group of animals, the middle aged-group (age 9 months), which 
may represent an intermediate phase between the early treatment effects and the late 
age recovery. The longitudinal study performed analyzed possible treatment effects also 
in contexts other than behavior such as volumetric examination and GFAP immuno-
reactivity of brain areas possibly involved in depression, and hippocampal cell prolifera-
tion.  No more treatment effects were detected in hippocampal neurogenesis, of course 
significantly diminished in later life (Rao et al., 2005), and in PFC and hippocampal vol-
umetric analysis in aged animals. GFAP densitometry revealed a treatment effect corre-
lated with age in all brain areas analyzed: CLI aged animals showedan an increased 
GFAP i-r compared to SAL aged animals, but the opposite trend was found in young ani-
mals. While in CLI young animals a reduction of GFAP density in hippocampus was ex-
pected, because of the observations in depressed patients (Drevets et al., 2008) and an-
imal models (Czeh et al., 2006; Gosselin et al., 2009), it is of difficult interpretation the 
trend found in aged rats: it is known that glia is highly activated in the old age (Unger, 
1998; Middeldorp and Hol, 2011), but our results seem to indicate that early-life expo-
sure to clomipramine potentiates astrocytic activation in later life, suggesting a rebound, 
maybe as a mechanism of recovery still in act. 
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Animals’ behavior has been studied in different paradigms, evaluating despair 
and helplessness in the FST, anhedonia in the SPT, and anxiety trait in the EPM test, in 
both basal and challenging conditions. Despite several studies reported about a motor 
hyperactivity in CLI animals (Hartley et al., 1990; Andersen et al., 2002; Maciag et al., 
2006), in our hands CLI animals, compared to Sal animals, showed a higher immobility 
and a lower climbing activity in the FST, as already observed by other authors  
(Velazquez-Moctezuma et al., 1993; Bhagya et al., 2008; Feng et al., 2008), and a lower 
distance moved assessed with the EPM test performed by stressed animals. It is not 
strange that contrasting results have been found in the evaluation of locomotor activity, 
considering that Hartley found that the performance of CLI rats differed in two distinct 
procedures of the open field test (Hartley et al., 1990). These observations cast some 
doubts on the predictability of tests for depressive symptoms, since behavioral charac-
terization is biased by the procedure and by the test adopted. Results herein reported 
are comparable throughout the three studies performed anyway: CLI animals showed 
motor hypoactivity and no anhedonic behavior. For what concern the absence of 
anhedonic behavior, our results confirmed the observations made by Vogel (Vogel et al., 
1990a). SPT and FST were useful not only to measure anhedonic and despair behavior 
respectively, but also to observe and evaluate animals’ reaction to factor “novelty”: all 
animals in a new context reacted in a certain degree and in a certain way. In the sucrose 
preference assessment, all animals, in the presence of two bottles of liquid, showed curi-
osity for the new setup of the cage environment, and showed an aggressive behavior 
when liquid and food were removed for the start of the 18h-deprivation period, trying to 
bite the experimenter. In the FST, animals, in both training and test sessions, vigorously 
struggle to escape from the cylinder during the first seconds in the water; only a very lit-
tle group of animals, that included both Sal and CLI rats, when put in the water in the 
test session stayed immobile for the very first seconds, showing a sort of learned help-
lessness behavior, but maybe it was due to the previous experience of training. These 
observations may suggest that CLI animals are animals that preserve a reactive instinct 
as Sal animals when put in a challenging situation, and consequently this could be the 
reason why we did not find strong behavioral abnormalities. Coming to these considera-
tions, we wanted to test the reaction of animals in extreme conditions, that were more 
stressful than the implicit stress that each behavioral test involves, and that could mime 
real life. We thought that laboratory animals are often too protected by operators from 
environment, with all that environment can includes: odors, noises, visual stimulators, 
handling carried out by more than one or two experimenters, sociality, predators and 
common dangers. If we want to build a valid animal model of depression, we possibly 
have to reproduce for animals conditions similar to daily human life, that is full of stress-
ful events . In order to fairly study animals’ reaction to a single stressful event, of simple 
and clean realization, we subjected animals to an acute event of restraint stress. As al-
ready described in section 4.1, restraint stress is a type of mild stressor, considered to 
be primarily a psychological stressor because it does not produce pain or direct physical 
insult (Girotti et al., 2006). Restraint stress was administered for a period of 4h in ani-
mals’ home cage in order to reduce possible spurious stress due to a different environ-
ment. Animals, when put in the restrainer, tried to escape from the trap without success 
and then moaned during the first minutes of the stressful event. With a sense of giving 
up, then all animals spent time staying immobile. The EPM test carried out in basal con-
ditions and after stress represented the ideal tool to assess, in a short period of time and 
without the need of training, the spontaneous behavior of animals. The investigation of 
anxiety trait in animals showed, in basal conditions, no differences due to early-life 
treatment with clomipramine in the several parameters evaluated, such as the amount 
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of time spent or entry frequency in open and closed arms or locomotor activity meas-
ured as distance moved on the maze. Animals spent the highest amount of time in closed 
arms, exhibiting a higher level of anxious than exploratory behavior, as previously de-
scribed by Andersen (Andersen et al., 2002; Andersen et al., 2010). In the second ses-
sion, rats that did not undergo acute stress showed no differences in the performance 
compared to the first session, as expected, while stress negatively affected locomotor ac-
tivity of restrained animals, even if animals did not show differences in amounts of time 
spent in the different zones of EPM. CLI animals resulted the most affected by stress, 
with a lower locomotor activity compared to Sal and Untr rats. This result shows that 
stress may induce the emersion of  behavioral correlates, such as hypoactivity, of a la-
tent depressive syndrome. Other depressive symptoms were found in the behavioral as-
sessment of the FST, with CLI animals that underwent restraint stress showing a de-
crease in climbing activity, another result that suggest a role for stress in extrapolating 
behavioral symptoms of depression, that in normal conditions are somehow hidden. The 
introduction of a third experimental group in Experiment 3 had its rationale in consid-
eration of the need of a real group of control, for both the treatment condition and the 
early-life manipulation. Untr animals were bred as more as possible as “wild” animals, 
the only handling that they received was due to litter change and supply of food and wa-
ter. Their body weight was not monitored during the period of treatment of CLI and Sal 
animals to avoid maternal separation even for some minutes per day. Thus Untr animals 
were not only animals that did not receive pharmacological treatment, they did not un-
dergo handling, maternal separation, temporary environmental switching, and pain due 
to injections. All these factors are considered by many authors as stressful events that 
can affect normal development of animals if occurred during the first post-natal days 
(Sterley et al., 2011). In an unexpected way, our study became more complex when the-
se remarks came out: were the symptoms found in adult animals realistically due to ne-
onatal clomipramine treatment rather to a series of chronic stressful events during ear-
ly-life? We cannot answer this question yet, because the experiment should have com-
prised one or more groups of animals to allow the evaluation of every single stressful 
factor that the reproduction of this animal model includes. It is widely known that neo-
natal manipulation, besides the way it is performed, has often reverberations on the 
normal development of both humans and animals.  
About behavioral differences between females and males, the neonatal clomi-
pramine model showed that females, in the two paradigms in which they were realted to 
males, that is to say FST and SPT, exhibited treatment effects, with CLI females, com-
pared to Sal females, spending a larger amount of time in immobility and a lower 
amount of time in climbing in the FST, and consuming less sucrose in the habituation 
phase of the SPT. At the light of these observations, three hypotheses are possible: 1) 
female rats have a higher a predisposition than males to develop depression within the 
paradigm here reported; 2) female rats have a higher tendency to express depressive-
like symptoms than males; 3) in this animal model of depression, females show a slower 
mechanism of recovery compared to males. We did not perform a longitudinal study for 
both males and females, but from our study, we learnt that females, observed at three 
different ages, have a gradual recovery from symptoms found in the young age. Unfortu-
nately, we do not know anything about the recovery rate of males, thus we cannot cast 
further hypothesis on gender differences in this animal model of depression.  
Neurogenesis studies performed were aimed at the investigation of a possible ef-
fect of early-life clomipramine treatment on hippocampal cell proliferation: neurogene-
sis is known to be decreased in stress-induced models of depression in rodents, as al-
ready said previously and, even if it has not been found decreased in postmortem stud-
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ies in the brain of depressed patients (Stockmeier et al., 2004), antidepressant treatment 
has been found to increase the number of newborn granule cells in rodents, as well as 
the number of progenitor cells in humans (Boldrini et al., 2009). The ‘neurogenic’ hy-
pothesis, although the few supporting data, is nowadays one of the guiding lines of re-
search on depression. With the awareness that early-life administration of clomipramine 
is a validated method to induce depression in animals, and realizing that no authors up 
to now have ever published in literature any data describing cell proliferation rate, dif-
ferentiation and survival in the hippocampus of CLI animals, we carried out an investiga-
tion that was aimed at the observation of neuronal proliferation in CLI animals com-
pared to Sal animals. With BrdU immunostaining we could evaluate the proliferation 
rate of all cells in the hippocampus: in Experiment 2 it was found that the total prolifera-
tion rate in the dentate gyrus of the hippocampus of CLI animals, both females and 
males, was decreased. DCX+ cells, that represent the total number of neurons born in the 
last three weeks of animal’s life, were not reduced in CLI animals. These observations 
suggest that even if total cell proliferation is decreased, the fraction represented by neu-
rons is intact, but, paradoxically, it seems increased, if we consider results achieved in 
Experiment 3: animals that did not receive any manipulation in the early life, thus repre-
senting the real control group, showed a lower number of DCX+ cells compared to both 
Sal and CLI animals. Since no neurogenesis studies were performed before animals were 
3 months old, thus no data about neurogenesis of the first days after the period of treat-
ment are available, we can only hypothesize that a mechanism of rebound is in act when 
animals are in that age.  
Morphological studies on DCX+ cells carried out with Neurolucida® in Experi-
ment 2 showed that females exhibited, in the parameters herein measured, smaller neu-
rons and in a certain degree neonatal clomipramine treatment induced in their cells an 
effect of decrease in the measure of somatic characteristics. Further, neonatal clomi-
pramine treatment seems to affect the total dendrite length of neurons of females and 
males in an opposite way: total dendritic length of DCX+ cells of CLI females showed to 
be shorter than Sal females. Thus, even if all CLI animals presented dendrites with dys-
trophic features at a first inspection, only in females there was a quantitative confirma-
tion.  
The investigation of GFAP i-r, to evaluate if the decreased hippocampal cell pro-
liferation is caused in part by a block of glial proliferation, as already observed in de-
pressed patients (Drevets et al., 2008), showed that astrocytic density was decreased in 
the hippocampal hilus of CLI young females, but not of males. As in the evaluation of be-
havioral results and neuronal morphology, CLI young females showed the effect of 
treatment occurred in the neonatal age, with all the regions analyzed affected, but CLI 
males did not exhibit the same results.  
Imaging studies herein reported did not corroborate the observations of a de-
creased hippocampal volume described in humans (Bremner et al., 2000; Sheline, 2000; 
MacQueen et al., 2003; Neumeister et al., 2005), but the result of the enlargement of lat-
eral ventricles in CLI animals, both females and males, maybe to the detriment of total 
brain volume, as in depressed, bipolar (Kempton et al., 2011), and schizophrenic 
(Kempton et al., 2010; Meduri et al., 2010) patients, may suggest that, in depression, cell 
loss occurs not only in hippocampus but also in other brain areas, and in addition it 
could be not the only mechanism by which ventricular volume gets bigger.  
Results from BDNF analysis, even if not novel (Cassano et al., 2006) constitute 
one of the few issues in which male rats showed the effect of neonatal clomipramine 
treatment. The reduced levels of this important growth factor in the hippocampus, in-
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volved in neuronal growth and differentiation, and associated with plasticity and surviv-
al of adult nerons and glia, is a confirmation, in this animal model, of the presence of 
some correlates of depression. The decrease in BDNF levels may be the cause of the 
qualitative morphological observations oof the presence of dystrophic features in hippo-
campal neurons of CLI rats.  In light of the results above discussed, it could be interest-
ing to perform an analysis of BDNF levels in females and in aged animals, in order to in-
vestigate gender and age differences in this context.  
A very important result, that can be correlated to data in literature about a study 
on the neonatal citalopram administration in rats and the consequent undefined syn-
drome induced by  treatment (Maciag et al., 2006; Weaver et al., 2010), is represented 
by the finding that SERT i-r is decreased in the hippocampus and cingulate cortex of CLI 
animals, two important regions of the limbic system, that is known to be particularly in-
volved in the pathophysiology of depression. Early-life exposure to clomipramine may 
affect, as already said, brain circuitry of serotonin of an organism that is not able to re-
spond because it has not enough defence mechanisms.  Disruption of SERT circuitry in 
these regions consequently can induce an impairments in cognitive processes that are 
not strongly reflected in behavioral abnormalities in our model. 
 
In conclusion, the present work provides evidence to some novel aspects of the 
neonatal clomipramine model of depression:  
• neurobiological issues herein investigated gave important indications about the 
correlation of the effects of early-life exposure to clomipramine with depression:  
no authors have ever described in literature data about hippocampal neuronal 
proliferation and morphology, astrocytic and SERT density, and MRI volumetry of 
brain are all issues that; 
• gender differences: no authors reported studies that involved both female and 
male rats. From behavioral to neurochemical investigations, significant differ-
ences were found about a major expression of correlates of depression in females 
than males, for reasons not clearly understood; 
• remission of symptoms in the elderly age: besides behavioral investigations, that 
were not completely novel (Vogel et al., 1990a; 2000)), astrocytic and neuronal 
investigations are novel important results that can further support the hypothe-
sis of a mechanism of recovery that induce the remission of tha abnormalities ob-
served; 
• response to stressors, even if analyses of locomotor activity in the novel enriched 
environment are still ongoing, showed to be controversial and cast some doubts 
on the real effector of the totality of symptoms up to now described in this animal 
model, if it is the pharmacological treatment itself or the stressful events implicit 
in the treatment routine.  
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7 Abbreviations 
ACTH adreno-cortico-tropin hormone 
BBB blood-brain barrier 
BDNF brain-derived nerve factor 
BrdU 5’-bromo-2’-deoxyuridine 
BrdU+ BrdU-labeled 
CLI clomipramine treated  
CNS central nervous system 
CRF corticotropin-releasing factor 
CRH corticotrophin releasing hormone 
DCX doublecortin 
DCX+ DCX-labeled 
DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders lV edn. Text Revised  
ECT electroconvulsive therapy  
EPM elevated plus maze 
FST forced swim test 
GFAP Glial fibrillary acidic protein 
GFAP i-r GFAP immunoreactivity 
HDACs histone deacetylases 
HPA hypothalamic pituitary adrenal 
IFN-α interferon-α 
IL interleukin 
MAOIs monoamino oxidase inhibitors 
MDD major depressive disorder 
MRI magnetic resonance imaging 
NPY neuropeptide Y 
OCD obsessive-compulsive disorder 
OD optical density 
PND post-natal day 
SD Sleep deprivation 
SPT sucrose preference test 
RSD REM sleep deprivation 
SAL saline treated 
SERT serotonin transporter 
SERT i-r SERT immune-reactive 
SSRI selective serotonin reuptake inhibitors  
TNF- α tumor necrosis factor α 
tPA tissue Plasminogen Activator 
TST tail suspension test 
WHO World Health Organization 
The clomipramine model of depression in the rat  79 
8 Bibliography 
(2000) Diagnostic and statistical manual of mental disorders : DSM-IV-TR. Washington, DC: American 
Psychiatric Association. 
Adrien J (2002) Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 
6:341-351. 
Aguilera G (1994) Regulation of pituitary ACTH secretion during chronic stress. Front 
Neuroendocrinol 15:321-350. 
Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitary-
adrenal axis: implications for stress adaptation. Regul Pept 96:23-29. 
Andersen SL, Dumont NL, Teicher MH (2002) Differences in behavior and monoamine laterality 
following neonatal clomipramine treatment. Dev Psychobiol 41:50-57. 
Andersen SL, Greene-Colozzi EA, Sonntag KC (2010) A novel, multiple symptom model of obsessive-
compulsive-like behaviors in animals. Biol Psychiatry 68:741-747. 
Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JJ, Mann JJ (2001) 
Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA 
expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25:892-
903. 
Arisi GM, Garcia-Cairasco N (2007) Doublecortin-positive newly born granule cells of hippocampus 
have abnormal apical dendritic morphology in the pilocarpine model of temporal lobe 
epilepsy. Brain Res 1165:126-134. 
Ashtari M, Greenwald BS, Kramer-Ginsberg E, Hu J, Wu H, Patel M, Aupperle P, Pollack S (1999) 
Hippocampal/amygdala volumes in geriatric depression. Psychol Med 29:629-638. 
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G (2010) Glial 
pathology in an animal model of depression: reversal of stress-induced cellular, metabolic 
and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501-
511. 
Barden N (2004) Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of 
depression. J Psychiatry Neurosci 29:185-193. 
Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E (2005) Antidepressant action of 
agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol 
Psychiatry 29:908-916. 
Barr AM, Hofmann CE, Weinberg J, Phillips AG (2002) Exposure to repeated, intermittent d-
amphetamine induces sensitization of HPA axis to a subsequent stressor. 
Neuropsychopharmacology 26:286-294. 
Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. 
Nat Rev Neurosci 7:137-151. 
Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, Almeida OF, Sousa N (2009) The 
mood-improving actions of antidepressants do not depend on neurogenesis but are 
associated with neuronal remodeling. Mol Psychiatry 14:764-773, 739. 
Bhagya V, Srikumar BN, Raju TR, Rao BS (2011) Chronic escitalopram treatment restores spatial 
learning, monoamine levels, and hippocampal long-term potentiation in an animal model of 
depression. Psychopharmacology (Berl) 214:477-494. 
Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS (2008) Neonatal clomipramine induced 
endogenous depression in rats is associated with learning impairment in adulthood. Behav 
Brain Res 187:190-194. 
Blanchard RJ, McKittrick CR, Blanchard DC (2001) Animal models of social stress: effects on behavior 
and brain neurochemical systems. Physiol Behav 73:261-271. 
80 Cristina Tognoli 
Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V (2009) 
Antidepressants increase neural progenitor cells in the human hippocampus. 
Neuropsychopharmacology 34:2376-2389. 
Bonilla-Jaime H, Retana-Marquez S, Arteaga-Silva M, Hernandez-Gonzalez M, Vazquez-Palacios G 
(2010) Circadian activity of corticosterone in an animal model of depression: response to 
muscarinic cholinergic stimulation. Physiol Behav 100:311-315. 
Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000) Hippocampal volume 
reduction in major depression. Am J Psychiatry 157:115-118. 
Bucan M, Abel T (2002) The mouse: genetics meets behaviour. Nat Rev Genet 3:114-123. 
Carlsson M, Carlsson A (1988) A regional study of sex differences in rat brain serotonin. Prog 
Neuropsychopharmacol Biol Psychiatry 12:53-61. 
Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE (2003) Follow-up of 
children of depressed mothers exposed or not exposed to antidepressant drugs during 
pregnancy. J Pediatr 142:402-408. 
Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC (2011) Length of prenatal exposure to 
selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation 
and psychomotor development. Psychopharmacology (Berl) 217:211-219. 
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite 
A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in 
the 5-HTT gene. Science 301:386-389. 
Cassano P, Hidalgo A, Burgos V, Adris S, Argibay P (2006) Hippocampal upregulation of the 
cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). 
Pharmacogenomics J 6:381-387. 
Castren E (2005) Is mood chemistry? Nat Rev Neurosci 6:241-246. 
Castren E, Rantamaki T (2010) The role of BDNF and its receptors in depression and antidepressant 
drug action: Reactivation of developmental plasticity. Dev Neurobiol 70:289-297. 
Charney DS (2004) Psychobiological mechanisms of resilience and vulnerability: implications for 
successful adaptation to extreme stress. Am J Psychiatry 161:195-216. 
Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, 
Hempstead BL, Lee FS (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-
related behavior. Science 314:140-143. 
Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and 
anxiety. Nat Rev Drug Discov 4:775-790. 
Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments 
and future needs. Trends Pharmacol Sci 23:238-245. 
Cryan JF, McGrath C, Leonard BE, Norman TR (1999) Onset of the effects of the 5-HT1A antagonist, 
WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-
DPAT-induced changes in the rat. Pharmacol Biochem Behav 63:333-338. 
Cryan JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying 
depression-related behavior in genetically modified mice. Mol Psychiatry 9:326-357. 
Cryan JF, Page ME, Lucki I (2005) Differential behavioral effects of the antidepressants reboxetine, 
fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. 
Psychopharmacology (Berl) 182:335-344. 
Czeh B, Simon M, Schmelting B, Hiemke C, Fuchs E (2006) Astroglial plasticity in the hippocampus is 
affected by chronic psychosocial stress and concomitant fluoxetine treatment. 
Neuropsychopharmacology 31:1616-1626. 
Dalla C, Antoniou K, Drossopoulou G, Xagoraris M, Kokras N, Sfikakis A, Papadopoulou-Daifoti Z 
(2005) Chronic mild stress impact: are females more vulnerable? Neuroscience 135:703-714. 
Dalla C, Edgecomb C, Whetstone AS, Shors TJ (2008) Females do not express learned helplessness 
like males do. Neuropsychopharmacology 33:1559-1569. 
Dalla C, Pitychoutis PM, Kokras N, Papadopoulou-Daifoti Z (2010) Sex differences in animal models of 
depression and antidepressant response. Basic Clin Pharmacol Toxicol 106:226-233. 
The clomipramine model of depression in the rat  81 
Dalla C, Pitychoutis PM, Kokras N, Papadopoulou-Daifoti Z (2011) Sex differences in response to 
stress and expression of depressive-like behaviours in the rat. Curr Top Behav Neurosci 8:97-
118. 
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness 
and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46-56. 
de Souza SL, Nogueira MI, de Jesus Deiro TC, de Castro FM, da Silva CM, da Silva MC, de Lira LO, 
Azmitia EC, de Castro RM (2004) Differential effects on somatic and reflex development by 
chronic clomipramine treatment. Physiol Behav 82:375-379. 
Deiro TC, Manhaes-de-Castro R, Cabral-Filho JE, Souza SL, Freitas-Silva SR, Ferreira LM, Guedes RC, 
Camara CR, Barros KM (2004) Neonatal administration of citalopram delays somatic 
maturation in rats. Braz J Med Biol Res 37:1503-1509. 
Delgado PL (2000) Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6:7-
11. 
Delgado y Palacios R, Campo A, Henningsen K, Verhoye M, Poot D, Dijkstra J, Van Audekerke J, 
Benveniste H, Sijbers J, Wiborg O, Van der Linden A (2011) Magnetic resonance imaging and 
spectroscopy reveal differential hippocampal changes in anhedonic and resilient subtypes of 
the chronic mild stress rat model. Biol Psychiatry 70:449-457. 
Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal 
neurogenesis affect learning and memory? Nat Rev Neurosci 11:339-350. 
Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. Biol 
Psychiatry 59:1136-1143. 
Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood 
disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213:93-
118. 
Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol 
Psychiatry 59:1116-1127. 
Dunn AJ, Swiergiel AH, de Beaurepaire R (2005) Cytokines as mediators of depression: what can we 
learn from animal studies? Neurosci Biobehav Rev 29:891-909. 
Ehninger D, Kempermann G (2008) Neurogenesis in the adult hippocampus. Cell Tissue Res 331:243-
250. 
Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, Verhaagen J, Nestler EJ (2003) 
Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a 
role in depression. Biol Psychiatry 54:994-1005. 
El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M, Costentin J, Adrien J, Vaugeois 
JM (2003) Behavioral, neurochemical, and electrophysiological characterization of a genetic 
mouse model of depression. Proc Natl Acad Sci U S A 100:6227-6232. 
Elfving B, Plougmann PH, Wegener G (2010) Detection of brain-derived neurotrophic factor (BDNF) in 
rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 
187:73-77. 
Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) 
Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317. 
Farmer J, Zhao X, van Praag H, Wodtke K, Gage FH, Christie BR (2004) Effects of voluntary exercise on 
synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley 
rats in vivo. Neuroscience 124:71-79. 
Fava M, Kendler KS (2000) Major depressive disorder. Neuron 28:335-341. 
Feng P, Ma Y, Vogel GW (2001) The critical window of brain development from susceptive to 
insusceptive. Effects of clomipramine neonatal treatment on sexual behavior. Brain Res Dev 
Brain Res 129:107-110. 
Feng P, Vurbic D, Wu Z, Hu Y, Strohl KP (2008) Changes in brain orexin levels in a rat model of 
depression induced by neonatal administration of clomipramine. J Psychopharmacol 22:784-
791. 
Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ (2004) Alterations of neuroplasticity in 
depression: the hippocampus and beyond. Eur Neuropsychopharmacol 14 Suppl 5:S481-490. 
82 Cristina Tognoli 
Fuchs E, Gould E (2000) Mini-review: in vivo neurogenesis in the adult brain: regulation and 
functional implications. Eur J Neurosci 12:2211-2214. 
Girotti M, Pace TW, Gaylord RI, Rubin BA, Herman JP, Spencer RL (2006) Habituation to repeated 
restraint stress is associated with lack of stress-induced c-fos expression in primary sensory 
processing areas of the rat brain. Neuroscience 138:1067-1081. 
Gosselin RD, Gibney S, O'Malley D, Dinan TG, Cryan JF (2009) Region specific decrease in glial 
fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. 
Neuroscience 159:915-925. 
Grassi Zucconi G, Cipriani S, Balgkouranidou I, Scattoni R (2006) 'One night' sleep deprivation 
stimulates hippocampal neurogenesis. Brain Res Bull 69:375-381. 
Gronli J, Bramham C, Murison R, Kanhema T, Fiske E, Bjorvatn B, Ursin R, Portas CM (2006) Chronic 
mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not 
in the hippocampus proper. Pharmacol Biochem Behav 85:842-849. 
Hajszan T, MacLusky NJ, Leranth C (2005) Short-term treatment with the antidepressant fluoxetine 
triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci 
21:1299-1303. 
Hartley P, Neill D, Hagler M, Kors D, Vogel G (1990) Procedure- and age-dependent hyperactivity in a 
new animal model of endogenous depression. Neurosci Biobehav Rev 14:69-72. 
Heim C, Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety 
disorders: preclinical and clinical studies. Biol Psychiatry 49:1023-1039. 
Holmes A, le Guisquet AM, Vogel E, Millstein RA, Leman S, Belzung C (2005a) Early life genetic, 
epigenetic and environmental factors shaping emotionality in rodents. Neurosci Biobehav 
Rev 29:1335-1346. 
Holmes A, Li Q, Koenig EA, Gold E, Stephenson D, Yang RJ, Dreiling J, Sullivan T, Crawley JN (2005b) 
Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in 
the tail suspension test for depression-related behavior. Psychopharmacology (Berl) 178:276-
285. 
Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 
23:477-501. 
Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. 
Annu Rev Psychol 61:81-109, C101-111. 
Ilin Y, Richter-Levin G (2009) Enriched environment experience overcomes learning deficits and 
depressive-like behavior induced by juvenile stress. PLoS One 4:e4329. 
Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL (2012) Depressive-like behavior induced 
by tumor necrosis factor-alpha in mice. Neuropharmacology 62:419-426. 
Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano 
A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety 
through blockade of anandamide hydrolysis. Nat Med 9:76-81. 
Kempermann G, Kuhn HG, Gage FH (1997) More hippocampal neurons in adult mice living in an 
enriched environment. Nature 386:493-495. 
Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S, Williams SC (2011) 
Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison 
with bipolar disorder. Arch Gen Psychiatry 68:675-690. 
Kempton MJ, Stahl D, Williams SC, DeLisi LE (2010) Progressive lateral ventricular enlargement in 
schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res 120:54-62. 
Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO, Harfstrand A, Eneroth P, Gustafsson JA 
(1988) Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity 
in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor 
immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the 
rostral ventromedial medulla. J Neural Transm 73:191-203. 
Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894-902. 
Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. 
Am J Psychiatry 167:1305-1320. 
The clomipramine model of depression in the rat  83 
Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-
induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the 
onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:744-759. 
Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C (2010) Regulation of brain-derived neurotrophic 
factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic 
antidepressant treatment. J Psychiatr Res 44:808-816. 
Lee T, Jarome T, Li SJ, Kim JJ, Helmstetter FJ (2009) Chronic stress selectively reduces hippocampal 
volume in rats: a longitudinal magnetic resonance imaging study. Neuroreport 20:1554-1558. 
Lucassen PJ, Meerlo P, Naylor AS, van Dam AM, Dayer AG, Fuchs E, Oomen CA, Czeh B (2010) 
Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: 
Implications for depression and antidepressant action. Eur Neuropsychopharmacol 20:1-17. 
Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA (2006) Neonatal antidepressant 
exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 
31:47-57. 
MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, Nahmias C, Young LT 
(2003) Course of illness, hippocampal function, and hippocampal volume in major 
depression. Proc Natl Acad Sci U S A 100:1387-1392. 
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) 
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future 
research and new drug developments in depression. Metab Brain Dis 24:27-53. 
Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC, Jr., Jones RM, 
Portoghese PS, Carlezon WA, Jr. (2003) Antidepressant-like effects of kappa-opioid receptor 
antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330. 
Maisonpierre PC, Le Beau MM, Espinosa R, 3rd, Ip NY, Belluscio L, de la Monte SM, Squinto S, Furth 
ME, Yancopoulos GD (1991) Human and rat brain-derived neurotrophic factor and 
neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 
10:558-568. 
Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases 
neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110. 
Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski SR, 
Balasubramani GK, Trivedi MH, Rush AJ (2005) Gender differences in depression: findings 
from the STAR*D study. J Affect Disord 87:141-150. 
Matys T, Pawlak R, Matys E, Pavlides C, McEwen BS, Strickland S (2004) Tissue plasminogen activator 
promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like 
behavior. Proc Natl Acad Sci U S A 101:16345-16350. 
Maudhuit C, Hamon M, Adrien J (1996) Effects of chronic treatment with zimelidine and REM sleep 
deprivation on the regulation of raphe neuronal activity in a rat model of depression. 
Psychopharmacology (Berl) 124:267-274. 
Mavanji V, Datta S (2002) Clomipramine treatment in neonatal rats alters the brain 
acetylcholinesterase activity in adulthood. Neurosci Lett 330:119-121. 
Meduri M, Bramanti P, Ielitro G, Favaloro A, Milardi D, Cutroneo G, Muscatello MR, Bruno A, Mico U, 
Pandolfo G, La Torre D, Vaccarino G, Anastasi G (2010) Morphometrical and morphological 
analysis of lateral ventricles in schizophrenia patients versus healthy controls. Psychiatry Res 
183:52-58. 
Meerlo P, Mistlberger RE, Jacobs BL, Heller HC, McGinty D (2009) New neurons in the adult brain: the 
role of sleep and consequences of sleep loss. Sleep Med Rev 13:187-194. 
Middeldorp J, Hol EM (2011) GFAP in health and disease. Prog Neurobiol 93:421-443. 
Ming GL, Song H (2005) Adult neurogenesis in the mammalian central nervous system. Annu Rev 
Neurosci 28:223-250. 
Mirmiran M, Scholtens J, van de Poll NE, Uylings HB, van der Gugten J, Boer GJ (1983) Effects of 
experimental suppression of active (REM) sleep during early development upon adult brain 
and behavior in the rat. Brain Res 283:277-286. 
84 Cristina Tognoli 
Mirmiran M, van de Poll NE, Corner MA, van Oyen HG, Bour HL (1981) Suppression of active sleep by 
chronic treatment with chlorimipramine during early postnatal development: effects upon 
adult sleep and behavior in the rat. Brain Res 204:129-146. 
Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990-2020: 
Global Burden of Disease Study. Lancet 349:1498-1504. 
Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff 
CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose 
interferon alfa. N Engl J Med 344:961-966. 
Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. 
Neuron 34:13-25. 
Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161-
1169. 
Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Bain EE, Charney DS, Drevets 
WC (2005) Reduced hippocampal volume in unmedicated, remitted patients with major 
depression versus control subjects. Biol Psychiatry 57:935-937. 
Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic 
electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547. 
O'Connor KA, Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, Maier SF (2003) 
Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain 
Res 991:123-132. 
O'Neil MF, Moore NA (2003) Animal models of depression: are there any? Hum Psychopharmacol 
18:239-254. 
Paizanis E, Hamon M, Lanfumey L (2007) Hippocampal neurogenesis, depressive disorders, and 
antidepressant therapy. Neural Plast 2007:73754. 
Palazidou E (2012) The neurobiology of depression. Br Med Bull 101:127-145. 
Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, Carpio C, Spitzer G, Santarelli L, Scharf B, Hen R, 
Rosoklija G, Sackeim HA, Dwork AJ (2007) Antidepressant-induced neurogenesis in the 
hippocampus of adult nonhuman primates. J Neurosci 27:4894-4901. 
Pies RW (2009) Depression and the pitfalls of causality: implications for DSM-V. J Affect Disord 116:1-
3. 
Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. 
Neuropsychopharmacology 33:88-109. 
Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z (2009) Neurochemical and 
behavioral alterations in an inflammatory model of depression: sex differences exposed. 
Neuroscience 159:1216-1232. 
Plumpe T, Ehninger D, Steiner B, Klempin F, Jessberger S, Brandt M, Romer B, Rodriguez GR, 
Kronenberg G, Kempermann G (2006) Variability of doublecortin-associated dendrite 
maturation in adult hippocampal neurogenesis is independent of the regulation of precursor 
cell proliferation. BMC Neurosci 7:77. 
Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for 
antidepressants. Arch Int Pharmacodyn Ther 229:327-336. 
Prathiba J, Kumar KB, Karanth KS (1998) Hyperactivity of hypothalamic pituitary axis in neonatal 
clomipramine model of depression. J Neural Transm 105:1335-1339. 
Prathiba J, Kumar KB, Karanth KS (2000) Effects of REM sleep deprivation on cholinergic receptor 
sensitivity and passive avoidance behavior in clomipramine model of depression. Brain Res 
867:243-245. 
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis 
of depression. Trends Immunol 27:24-31. 
Rao MS, Hattiangady B, Abdel-Rahman A, Stanley DP, Shetty AK (2005) Newly born cells in the ageing 
dentate gyrus display normal migration, survival and neuronal fate choice but endure 
retarded early maturation. Eur J Neurosci 21:464-476. 
The clomipramine model of depression in the rat  85 
Rao MS, Shetty AK (2004) Efficacy of doublecortin as a marker to analyse the absolute number and 
dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci 
19:234-246. 
Reich CG, Taylor ME, McCarthy MM (2009) Differential effects of chronic unpredictable stress on 
hippocampal CB1 receptors in male and female rats. Behav Brain Res 203:264-269. 
Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F (1994) Hypothalamic-pituitary-
adrenocortical axis changes in the rat after long-term treatment with the reversible 
monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60:509-519. 
Reul JM, Stec I, Soder M, Holsboer F (1993) Chronic treatment of rats with the antidepressant 
amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. 
Endocrinology 133:312-320. 
Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR (2009) 
Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk 
of depression: a meta-analysis. JAMA 301:2462-2471. 
Rivera-Baltanas T, Olivares JM, Calado-Otero M, Kalynchuk LE, Martinez-Villamarin JR, Caruncho HJ 
(2012) Serotonin transporter clustering in blood lymphocytes as a putative biomarker of 
therapeutic efficacy in major depressive disorder. J Affect Disord 137:46-55. 
Rodgers RJ, Dalvi A (1997) Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 
21:801-810. 
Rygula R, Abumaria N, Flugge G, Fuchs E, Ruther E, Havemann-Reinecke U (2005) Anhedonia and 
motivational deficits in rats: impact of chronic social stress. Behav Brain Res 162:127-134. 
Sahay A, Hen R (2007) Adult hippocampal neurogenesis in depression. Nat Neurosci 10:1110-1115. 
Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R (2005) Selective serotonin reuptake inhibitors in 
pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365:482-
487. 
Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch 
Gen Psychiatry 57:925-935. 
Schmidt HD, Duman RS (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, 
antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 
18:391-418. 
Sheline YI (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of 
stress and medical comorbidity. Biol Psychiatry 48:791-800. 
Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor 
produces antidepressant effects in behavioral models of depression. J Neurosci 22:3251-
3261. 
Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G (2004) Age-dependent reductions in 
the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. 
Neuropsychopharmacology 29:2088-2096. 
Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like effect of brain-derived 
neurotrophic factor (BDNF). Pharmacol Biochem Behav 56:131-137. 
Slezak M, Pfrieger FW (2003) New roles for astrocytes: regulation of CNS synaptogenesis. Trends 
Neurosci 26:531-535. 
Smith GS, Kahn A, Sacher J, Rusjan P, van Eimeren T, Flint A, Wilson AA (2011) Serotonin transporter 
occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. 
Am J Geriatr Psychiatry 19:1016-1025. 
Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression 
of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J 
Neurosci 15:1768-1777. 
Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci 
Biobehav Rev 29:627-647. 
Stein DJ, Goodman WK, Rauch SL (2000) The cognitive-affective neuroscience of obsessive-
compulsive disorder. Curr Psychiatry Rep 2:341-346. 
86 Cristina Tognoli 
Sterley TL, Howells FM, Russell VA (2011) Effects of early life trauma are dependent on genetic 
predisposition: a rat study. Behav Brain Funct 7:11. 
Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, 
Rajkowska G (2004) Cellular changes in the postmortem hippocampus in major depression. 
Biol Psychiatry 56:640-650. 
Strekalova T, Spanagel R, Bartsch D, Henn FA, Gass P (2004) Stress-induced anhedonia in mice is 
associated with deficits in forced swimming and exploration. Neuropsychopharmacology 
29:2007-2017. 
Uher R, McGuffin P (2010) The moderation by the serotonin transporter gene of environmental 
adversity in the etiology of depression: 2009 update. Mol Psychiatry 15:18-22. 
Unger JW (1998) Glial reaction in aging and Alzheimer's disease. Microsc Res Tech 43:24-28. 
Urani A, Chourbaji S, Gass P (2005) Mutant mouse models of depression: candidate genes and 
current mouse lines. Neurosci Biobehav Rev 29:805-828. 
Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA (2000) 
Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging 
study. Biol Psychiatry 47:1087-1090. 
Velazquez-Moctezuma J, Aguilar-Garcia A, Diaz-Ruiz O (1993) Behavioral effects of neonatal 
treatment with clomipramine, scopolamine, and idazoxan in male rats. Pharmacol Biochem 
Behav 46:215-217. 
Vijayakumar M, Meti BL (1999) Alterations in the levels of monoamines in discrete brain regions of 
clomipramine-induced animal model of endogenous depression. Neurochem Res 24:345-349. 
Vogel G, Hartley P, Neill D, Hagler M, Kors D (1988) Animal depression model by neonatal 
clomipramine: reduction of shock induced aggression. Pharmacol Biochem Behav 31:103-
106. 
Vogel G, Neill D, Hagler M, Kors D (1990a) A new animal model of endogenous depression: a 
summary of present findings. Neurosci Biobehav Rev 14:85-91. 
Vogel G, Neill D, Kors D, Hagler M (1990b) REM sleep abnormalities in a new animal model of 
endogenous depression. Neurosci Biobehav Rev 14:77-83. 
Vollmayr B, Henn FA (2001) Learned helplessness in the rat: improvements in validity and reliability. 
Brain Res Brain Res Protoc 8:1-7. 
Ward HE, Johnson EA, Salm AK, Birkle DL (2000) Effects of prenatal stress on defensive withdrawal 
behavior and corticotropin releasing factor systems in rat brain. Physiol Behav 70:359-366. 
Warner-Schmidt JL, Duman RS (2006) Hippocampal neurogenesis: opposing effects of stress and 
antidepressant treatment. Hippocampus 16:239-249. 
Weaver KJ, Paul IA, Lin RC, Simpson KL (2010) Neonatal exposure to citalopram selectively alters the 
expression of the serotonin transporter in the hippocampus: dose-dependent effects. Anat 
Rec (Hoboken) 293:1920-1932. 
Wiegers GJ, Croiset G, Reul JM, Holsboer F, de Kloet ER (1993) Differential effects of corticosteroids 
on rat peripheral blood T-lymphocyte mitogenesis in vivo and in vitro. Am J Physiol 265:E825-
830. 
Willner P, Mitchell PJ (2002) The validity of animal models of predisposition to depression. Behav 
Pharmacol 13:169-188. 
Wolf OT, Dyakin V, Vadasz C, de Leon MJ, McEwen BS, Bulloch K (2002) Volumetric measurement of 
the hippocampus, the anterior cingulate cortex, and the retrosplenial granular cortex of the 
rat using structural MRI. Brain Res Brain Res Protoc 10:41-46. 
Wrynn AS, Mac Sweeney CP, Franconi F, Lemaire L, Pouliquen D, Herlidou S, Leonard BE, Gandon J, 
de Certaines JD (2000) An in-vivo magnetic resonance imaging study of the olfactory 
bulbectomized rat model of depression. Brain Res 879:193-199. 
Yoo HS, Bunnell BN, Crabbe JB, Kalish LR, Dishman RK (2000) Failure of neonatal clomipramine 
treatment to alter forced swim immobility: chronic treadmill or activity-wheel running and 
imipramine. Physiol Behav 70:407-411. 
